Clinical trials inventory: every registered trial per peptide

This inventory lists every trial registered on ClinicalTrials.gov whose intervention is one of the peptides covered on PeptideWikis — 3066 trials across 37 peptides (3303 listings: a trial that tests two of them, such as a combination, is listed under each), pulled from the registry’s public API. It answers one question per peptide: how much human testing exists, at what phase, and whether results were posted. A registered trial is not evidence of an effect; see each peptide’s entry for what the trials found.

Item	Detail
Source	ClinicalTrials.gov API v2, intervention search
Last checked	2026-11-11
Refresh	daily, automated; published when a trial is added or changes status
Cite as	PeptideWikis Editorial Team, “Clinical trials inventory”, peptidewikis.com, checked 2026-11-11

Summary

Peptide	Registered trials	Phase 3 or later · results posted
5-Amino-1MQ	0	0 · 0
AOD-9604	0	0 · 0
BPC-157	3	0 · 0
bremelanotide (PT-141)	10	5 · 4
cagrilintide	45	23 · 1
CagriSema	36	21 · 1
Cerebrolysin	43	21 · 3
CJC-1295	1	0 · 0
Dihexa	0	0 · 0
DSIP	0	0 · 0
elamipretide (SS-31)	22	5 · 14
epitalon	1	0 · 0
GHK-Cu	24	7 · 3
IGF-1 LR3	0	0 · 0
ipamorelin	3	0 · 0
Kisspeptin	36	3 · 7
KPV	0	0 · 0
liraglutide	521	246 · 145
mazdutide	45	16 · 1
melanotan II	23	6 · 12
MOTS-c	4	0 · 0
Nisotirostide	0	0 · 0
orforglipron	53	29 · 28
oxytocin	938	187 · 163
Pinealon	0	0 · 0
retatrutide	33	14 · 3
Selank	2	0 · 0
semaglutide	802	309 · 112
Semax	0	0 · 0
sermorelin	27	5 · 11
SLU-PP-332	0	0 · 0
survodutide	29	12 · 2
TB-500	17	4 · 8
Teriparatide	182	82 · 63
tesamorelin	23	4 · 10
thymosin alpha-1	67	19 · 2
tirzepatide	313	109 · 47

5-Amino-1MQ: 0 registered trials

No registered trial names this peptide as an intervention (intervention search; a trial filed under another name or a combination product would not appear here).

AOD-9604: 0 registered trials

No registered trial names this peptide as an intervention (intervention search; a trial filed under another name or a combination product would not appear here).

BPC-157: 3 registered trials

Trial	Title	Status
NCT07803250 Phase 1 · n=30 · 2027	Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery University of Arkansas · Rotator Cuff Tear	Not Yet Recruiting
NCT07752381 n/a · n=40 · 2025	A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery Parlay Wellness · Musculoskeletal Inflammation, Exercise-Induced Muscle Damage	Completed
NCT02637284 Phase 1 · n=42 · 2015	PCO-02 – Safety and Pharmacokinetics Trial PharmaCotherapia d.o.o. · Healthy Volunteers	Unknown

bremelanotide (PT-141): 10 registered trials

Trial	Title	Status
NCT06867835 Phase 4 · n=10 · 2025	Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk Cosette Pharmaceuticals, Inc. · Lactating Mother	Completed
NCT06565611 Phase 2 · n=108 · 2024	A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity Palatin Technologies, Inc · Obesity	Active Not Recruiting
NCT05709444 Phase 2 · n=16 · 2022	A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease Palatin Technologies, Inc · Kidney Disease	Completed
NCT04943068 Phase 3 · n=193 · 2021	A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Kwang Dong Pharmaceutical co., ltd. · Hypoactive Sexual Desire Disorder	Completed
NCT04179734 Phase 4 · n=40 · 2019 · results posted	Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder Imperial College Healthcare NHS Trust · Hypoactive Sexual Desire Disorder	Completed
NCT03973047 Phase 1 · n=228 · 2019	Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran AMAG Pharmaceuticals, Inc. · Nausea	Completed
NCT02338960 Phase 3 · n=714 · 2015 · results posted	2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Palatin Technologies, Inc · Hypoactive Sexual Desire Disorder	Completed
NCT02333071 Phase 3 · n=723 · 2014 · results posted	1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Palatin Technologies, Inc · Hypoactive Sexual Desire Disorder	Completed
NCT01382719 Phase 2 · n=612 · 2011 · results posted	Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder Palatin Technologies, Inc · Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder	Completed
NCT00425256 Phase 2 · 2006	Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) Palatin Technologies, Inc · Sexual Arousal Disorder	Completed

cagrilintide: 45 registered trials

Trial	Title	Status
NCT07919405 Phase 3 · n=1408 · 2026	A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obe Novo Nordisk A/S · Hypertension, Obesity	Not Yet Recruiting
NCT07817251 Phase 3 · n=210 · 2026	Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema Novo Nordisk A/S · Diabetes Mellitus, Type 2	Recruiting
NCT07357740 Phase 2 · 2026	A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes Novo Nordisk A/S · Diabetes Mellitus, Type 2	Withdrawn
NCT07745504 Phase 3 · n=285 · 2026	A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight Novo Nordisk A/S · Overweight, Obesity	Recruiting
NCT07282613 Phase 3 · n=80 · 2026	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Di Novo Nordisk A/S · Diabetes Mellitus, Type 2	Recruiting
NCT07357766 Phase 3 · 2026	A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight Novo Nordisk A/S · Overweight, Obesity	Withdrawn
NCT07607587 Phase 1 · n=114 · 2026	Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events Novo Nordisk A/S · Obesity, Overweight	Recruiting
NCT07564414 Phase 3 · n=2500 · 2026	A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Novo Nordisk A/S · Obesity, Type 2 Diabetes	Recruiting
NCT07605052 Phase 1 · n=50 · 2026	A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight Novo Nordisk A/S · Overweight, Obesity	Completed
NCT07597018 Phase 1 · n=234 · 2026	A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweigh Novo Nordisk A/S · Obesity, Overweight	Recruiting
NCT07557953 Phase 1 · n=120 · 2026	A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity Novo Nordisk A/S · Overweight, Obesity	Recruiting
NCT07527195 Phase 1 · n=100 · 2026	Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) Novo Nordisk A/S · Obesity	Recruiting
NCT07411560 Phase 1 · n=100 · 2026	A Study Looking at How Weekly Injections of Two Hormones – GIP and Amylin – Affect Stomach-related Side Effects in People Who Are Overweight Novo Nordisk A/S · Overweight, Obese	Recruiting
NCT07253285 Phase 3 · n=460 · 2026	A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight Novo Nordisk A/S · Overweight, Obesity	Recruiting
NCT07220759 Phase 3 · n=330 · 2025	Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide Novo Nordisk A/S · Overweight, Obesity	Active Not Recruiting
NCT07220642 Phase 3 · n=300 · 2025	Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide Novo Nordisk A/S · Obesity, Overweight	Active Not Recruiting
NCT07184086 Phase 1 · n=80 · 2025	A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet Novo Nordisk A/S · Obesity	Active Not Recruiting
NCT07010432 Phase 1 · n=144 · 2025	The Role of the Amylin Analogue Cagrilintide in Bone Metabolism Novo Nordisk A/S · Obesity	Recruiting
NCT07011667 Phase 3 · n=609 · 2025	A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term Novo Nordisk A/S · Obesity	Active Not Recruiting
NCT06780449 Phase 3 · n=400 · 2025	A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity Novo Nordisk A/S · Obesity	Active Not Recruiting
NCT06797869 Phase 2 · n=142 · 2025	A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Novo Nordisk A/S · Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy	Completed
NCT06719011 Phase 1 · n=178 · 2024	A Study on How NNC0174-1213 Works in People With Overweight or Obesity. Novo Nordisk A/S · Obesity, Overweight	Completed
NCT06716307 Phase 1 · n=18 · 2024	A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Novo Nordisk A/S · Obesity	Completed
NCT06534411 Phase 3 · n=1023 · 2024	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated Novo Nordisk A/S · Diabetes Mellitus, Type 2	Completed
NCT06388187 Phase 3 · n=300 · 2024	A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight Novo Nordisk A/S · Obesity	Completed
NCT06409130 Phase 2 · n=270 · 2024	Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-relat Novo Nordisk A/S · Alcohol-related Liver Disease	Completed
NCT06403761 Phase 1 · n=158 · 2024	Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes Novo Nordisk A/S · Diabetes Mellitus, Type 2	Completed
NCT06131372 Phase 2 · n=626 · 2024	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Novo Nordisk A/S · Chronic Kidney Disease, Type 2 Diabetes	Completed
NCT06323161 Phase 3 · n=274 · 2024	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated Wit Novo Nordisk A/S · Type 2 Diabetes	Completed
NCT06323174 Phase 3 · n=189 · 2024	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated Wit Novo Nordisk A/S · Type 2 Diabetes	Completed
NCT06289504 Phase 1 · n=34 · 2024	A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight Novo Nordisk A/S · Obesity	Completed
NCT06207877 Phase 1 · n=62 · 2024	A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight Novo Nordisk A/S · Obesity	Completed
NCT06267092 Phase 1 · n=164 · 2024	A Study of How CagriSema Works on Appetite in People With Excess Body Weight Novo Nordisk A/S · Overweight, Obesity	Completed
NCT06221969 Phase 3 · n=1024 · 2024	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated Novo Nordisk A/S · Type 2 Diabetes	Completed
NCT06131437 Phase 3 · n=809 · 2023	A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight Novo Nordisk A/S · Obesity	Completed
NCT06065540 Phase 3 · n=2734 · 2023	A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People Wi Novo Nordisk A/S · Type 2 Diabetes Mellitus	Completed
NCT05996848 Phase 3 · n=300 · 2023	A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight Novo Nordisk A/S · Obesity or Overweight	Completed
NCT05804162 Phase 1 · n=107 · 2023	A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants Novo Nordisk A/S · Obesity	Completed
NCT05564104 Phase 1 · n=32 · 2023	A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Novo Nordisk A/S · Hepatic Impairment, Healthy Volunteers	Completed
NCT05813925 Phase 3 · n=331 · 2023	A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight Novo Nordisk A/S · Obesity or Overweight	Completed

Showing the 40 most recent of 45.

CagriSema: 36 registered trials

Trial	Title	Status
NCT07919405 Phase 3 · n=1408 · 2026	A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obe Novo Nordisk A/S · Hypertension, Obesity	Not Yet Recruiting
NCT07817251 Phase 3 · n=210 · 2026	Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema Novo Nordisk A/S · Diabetes Mellitus, Type 2	Recruiting
NCT07357740 Phase 2 · 2026	A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes Novo Nordisk A/S · Diabetes Mellitus, Type 2	Withdrawn
NCT07745504 Phase 3 · n=285 · 2026	A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight Novo Nordisk A/S · Overweight, Obesity	Recruiting
NCT07282613 Phase 3 · n=80 · 2026	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Di Novo Nordisk A/S · Diabetes Mellitus, Type 2	Recruiting
NCT07357766 Phase 3 · 2026	A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight Novo Nordisk A/S · Overweight, Obesity	Withdrawn
NCT07564414 Phase 3 · n=2500 · 2026	A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Novo Nordisk A/S · Obesity, Type 2 Diabetes	Recruiting
NCT07597018 Phase 1 · n=234 · 2026	A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweigh Novo Nordisk A/S · Obesity, Overweight	Recruiting
NCT07527195 Phase 1 · n=100 · 2026	Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) Novo Nordisk A/S · Obesity	Recruiting
NCT07253285 Phase 3 · n=460 · 2026	A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight Novo Nordisk A/S · Overweight, Obesity	Recruiting
NCT07184086 Phase 1 · n=80 · 2025	A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet Novo Nordisk A/S · Obesity	Active Not Recruiting
NCT07010432 Phase 1 · n=144 · 2025	The Role of the Amylin Analogue Cagrilintide in Bone Metabolism Novo Nordisk A/S · Obesity	Recruiting
NCT07011667 Phase 3 · n=609 · 2025	A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term Novo Nordisk A/S · Obesity	Active Not Recruiting
NCT06780449 Phase 3 · n=400 · 2025	A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity Novo Nordisk A/S · Obesity	Active Not Recruiting
NCT06797869 Phase 2 · n=142 · 2025	A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Novo Nordisk A/S · Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy	Completed
NCT06716307 Phase 1 · n=18 · 2024	A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Novo Nordisk A/S · Obesity	Completed
NCT06534411 Phase 3 · n=1023 · 2024	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated Novo Nordisk A/S · Diabetes Mellitus, Type 2	Completed
NCT06388187 Phase 3 · n=300 · 2024	A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight Novo Nordisk A/S · Obesity	Completed
NCT06409130 Phase 2 · n=270 · 2024	Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-relat Novo Nordisk A/S · Alcohol-related Liver Disease	Completed
NCT06403761 Phase 1 · n=158 · 2024	Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes Novo Nordisk A/S · Diabetes Mellitus, Type 2	Completed
NCT06131372 Phase 2 · n=626 · 2024	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Novo Nordisk A/S · Chronic Kidney Disease, Type 2 Diabetes	Completed
NCT06323161 Phase 3 · n=274 · 2024	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated Wit Novo Nordisk A/S · Type 2 Diabetes	Completed
NCT06323174 Phase 3 · n=189 · 2024	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated Wit Novo Nordisk A/S · Type 2 Diabetes	Completed
NCT06289504 Phase 1 · n=34 · 2024	A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight Novo Nordisk A/S · Obesity	Completed
NCT06207877 Phase 1 · n=62 · 2024	A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight Novo Nordisk A/S · Obesity	Completed
NCT06267092 Phase 1 · n=164 · 2024	A Study of How CagriSema Works on Appetite in People With Excess Body Weight Novo Nordisk A/S · Overweight, Obesity	Completed
NCT06221969 Phase 3 · n=1024 · 2024	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated Novo Nordisk A/S · Type 2 Diabetes	Completed
NCT06131437 Phase 3 · n=809 · 2023	A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight Novo Nordisk A/S · Obesity	Completed
NCT06065540 Phase 3 · n=2734 · 2023	A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People Wi Novo Nordisk A/S · Type 2 Diabetes Mellitus	Completed
NCT05996848 Phase 3 · n=300 · 2023	A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight Novo Nordisk A/S · Obesity or Overweight	Completed
NCT05813925 Phase 3 · n=331 · 2023	A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight Novo Nordisk A/S · Obesity or Overweight	Completed
NCT05669755 Phase 3 · n=7101 · 2023	REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels Novo Nordisk A/S · Cardiovascular Disease	Active Not Recruiting
NCT05394519 Phase 3 · n=1200 · 2023	A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight Novo Nordisk A/S · Overweight, Obesity	Completed
NCT05567796 Phase 3 · n=3400 · 2022	A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Novo Nordisk A/S · Obesity	Active Not Recruiting
NCT04982575 Phase 2 · n=92 · 2021 · results posted	Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes Novo Nordisk A/S · Diabetes Mellitus, Type 2	Completed
NCT04940078 Phase 1 · n=40 · 2021	A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight Novo Nordisk A/S · Obesity & Overweight	Completed

Cerebrolysin: 43 registered trials

Trial	Title	Status
NCT07846488 n/a · n=440 · 2026	Combined Acupuncture-Based Therapy for Rehabilitation After Ischemic Stroke National Hospital of Acupuncture, Vietnam · Ischemic Stroke, Hemiplegia	Not Yet Recruiting
NCT06339411 Phase 2 · n=100 · 2026	Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy Chang Gung Memorial Hospital · Acute Ischemic Stroke	Not Yet Recruiting
NCT06899464 Phase 4 · n=30 · 2025	Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage – a Prospective Randomized Open Blinded En Cardinal Stefan Wyszynski University · Intracerebral Hemorrhage, Hemorrhagic Stroke, Intracerebral	Not Yet Recruiting
NCT07043686 n/a · n=30 · 2025	Cerebrolysin in Early Stroke Rehabilitation – Tertiary Study University Medical Centre Ljubljana · Ischemic Stroke, Acute, Rehabilitation Outcome	Recruiting
NCT06897176 Phase 4 · n=40 · 2025	Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, S Yonsei University · Stroke	Recruiting
NCT06489925 Early Phase 1 · n=20 · 2024	Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion University Hospital Sestre Milosrdnice · Basilar Artery Occlusion, Posterior Circulation Brain Infarction	Unknown
NCT06677502 n/a · n=500 · 2024	Cerebrolysin in Critically Ill Patients With Delirium Medical University of Lublin · Cognitive Impairment	Enrolling By Invitation
NCT05755997 Phase 2 · n=30 · 2023	CERebrolysin In CADASIL Ever Neuro Pharma GmbH · Cadasil	Active Not Recruiting
NCT06070753 n/a · n=30 · 2023	A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergo Shaare Zedek Medical Center · Acute Ischemic Stroke	Unknown
NCT06052787 Phase 3 · n=150 · 2023	Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU Ain Shams University · Traumatic Brain Injury	Completed
NCT05821075 Phase 1/Phase 2 · n=90 · 2023	Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy October 6 University · Bell Palsy	Recruiting
NCT04427241 Phase 4 · n=12 · 2023	Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness Konkuk University Medical Center · Disorder of Consciousness, Hemorrhagic Stroke	Recruiting
NCT05864677 n/a · n=100 · 2023	Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery Medical University of Lublin · Neurocognitive Disorders, Surgery-Complications	Unknown
NCT06078215 Phase 4 · n=350 · 2023	CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke Poznan University of Medical Sciences · Acute Ischemic Stroke	Unknown
NCT06273020 Phase 4 · n=60 · 2022	Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke Hospital Universitario Dr. Jose E. Gonzalez · Ischemic Stroke, Acute, Diabetes Mellitus, Type 2	Unknown
NCT06208540 Phase 4 · n=160 · 2021	Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants Sherifa Ahmed Hamed · Post-covid-19 Persistent Smell and Taste Disorders	Completed
NCT04124367 Phase 2 · n=4 · 2021	IMPULSE – StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE Ever Neuro Pharma GmbH · Chronic Stroke, Subacute Stroke	Terminated
NCT04913831 Phase 4 · n=30 · 2021	Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized C Yonsei University · Stroke	Unknown
NCT05124353 Phase 2/Phase 3 · n=100 · 2021	Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT Pomeranian Medical University Szczecin · Stroke, Acute, Ischemic	Unknown
NCT06429943 n/a · n=47 · 2021	Cerebrolysin in SAH (Subarachnoidal Haemorrhage) – Observational Study Pomeranian Medical University Szczecin · SAH (Subarachnoid Hemorrhage)	Completed
NCT04904341 Phase 3 · n=50 · 2021	Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke. Military Institute od Medicine National Research Institute · Stroke, Ischemic, Stroke, Acute	Unknown
NCT04830943 Phase 3 · n=250 · 2020	Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia Assiut University · Covid19 Related Anosmia and Aguesia	Completed
NCT05807503 n/a · n=56 · 2020	Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain Injury Pomeranian Medical University Szczecin · TBI (Traumatic Brain Injury)	Completed
NCT03480698 n/a · n=1851 · 2018	Cerebrolysin REGistry Study in Stroke – a High-quality Observational Study of Comparative Effectiveness Ever Neuro Pharma GmbH · Acute Ischemic Stroke	Completed
NCT04751136 Phase 2 · n=64 · 2016	the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome Mansoura University Children Hospital · Down Syndrome	Completed
NCT03506841 Phase 1 · n=60 · 2016	Cerebrolysin and Neurodevelopment in Preterm Infants Mansoura University Children Hospital · Infant Development, Cerebral Palsy	Completed
NCT02768571 Phase 4 · n=80 · 2016	Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke Samsung Medical Center · Stroke	Completed
NCT02581371 Phase 4 · n=30 · 2015	Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Clinical Institute of the Brain, Russia · Ischemic Stroke	Unknown
NCT05288465 n/a · n=5 · 2014	Hair Repigmentation During Cerebrolysin Therapy Universidad Autonoma de Nuevo Leon · Hair Problems	Completed
NCT02541227 n/a · n=1823 · 2014	Cerebrolysin REGistry Study in Stroke Ever Neuro Pharma GmbH · Ischemic Stroke	Terminated
NCT02116348 Phase 2 · n=100 · 2014	Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy Ain Shams University · Cerebral Palsy Children, Children With Traumatic Brain Injury	Unknown
NCT01787123 Phase 2/Phase 3 · n=50 · 2013	Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachn Kwong Wah Hospital · Subarachnoid Hemorrhage, Intracranial Aneurysm	Completed
NCT01606111 Phase 4 · n=46 · 2013	The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Ever Neuro Pharma GmbH · Traumatic Brain Injury	Terminated
NCT01556854 n/a · n=20000 · 2011	Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke yongjun wang · Acute Ischemic Stroke	Unknown
NCT01059461 Phase 2 · n=40 · 2011	Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic Encephalopathy Sahar M.A. Hassanein, MD · Hypoxic-Ischemic Encephalopathy	Completed
NCT01996761 Phase 4 · n=71 · 2011	Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke Samsung Medical Center · Cerebrolysin	Completed
NCT01388738 Phase 3 · n=30 · 2011	Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke. Clinical Institute of the Brain, Russia · Stroke	Completed
NCT02149875 Phase 1/Phase 2 · n=84 · 2010 · results posted	Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke Shanghai 6th People's Hospital · Acute Cerebral Stroke Within 12 Hours for the First Time	Completed
NCT00947531 Phase 4 · n=242 · 2006 · results posted	A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Ever Neuro Pharma GmbH · Vascular Dementia	Completed
NCT00868283 Phase 4 · n=1071 · 2006	The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke Ever Neuro Pharma GmbH · Ischemic Stroke	Completed

Showing the 40 most recent of 43.

CJC-1295: 1 registered trial

Trial	Title	Status
NCT00267527 Phase 2 · n=120 · 2005	A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity ConjuChem · Obesity, HIV Infections	Terminated

Dihexa: 0 registered trials

No registered trial names this peptide as an intervention (intervention search; a trial filed under another name or a combination product would not appear here).

DSIP: 0 registered trials

No registered trial names this peptide as an intervention (intervention search; a trial filed under another name or a combination product would not appear here).

elamipretide (SS-31): 22 registered trials

Trial	Title	Status
NCT07927972 Phase 1 · n=6 · 2026	Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syn Stealth BioTherapeutics Inc. · Barth Syndrome	Not Yet Recruiting
NCT07531251 Phase 4 · n=48 · 2026	Clinical Trial in Patients With Barth Syndrome- 4TAZPower Stealth BioTherapeutics Inc. · Barth Syndrome	Recruiting
NCT07275424 Phase 2 · n=30 · 2025	Study of Healthy Aging and Physical Function With Elamipretide David Marcinek · Aging, Healthy	Recruiting
NCT06373731 Phase 3 · n=313 · 2024	ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macul Stealth BioTherapeutics Inc. · Age Related Macular Degeneration (ARMD)	Active Not Recruiting
NCT05162768 Phase 3 · n=102 · 2022	Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) Stealth BioTherapeutics Inc. · Mitochondrial Myopathies, Mitochondrial Pathology	Completed
NCT05168774 Phase 1/Phase 2 · n=20 · 2022 · results posted	FRDA Investigator Initiated Study (IIS) With Elamipretide Children's Hospital of Philadelphia · Friedreich Ataxia	Completed
NCT03891875 Phase 2 · n=176 · 2019 · results posted	ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA Stealth BioTherapeutics Inc. · Age-related Macular Degeneration	Completed
NCT03323749 Phase 3 · n=218 · 2017 · results posted	A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension Stealth BioTherapeutics Inc. · Primary Mitochondrial Myopathy	Terminated
NCT03098797 Phase 2/Phase 3 · n=12 · 2017 · results posted	A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome Stealth BioTherapeutics Inc. · Barth Syndrome	Completed
NCT02976038 Phase 2 · n=28 · 2016 · results posted	Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Prim Stealth BioTherapeutics Inc. · Primary Mitochondrial Disease	Terminated
NCT02848313 Phase 1 · n=40 · 2016 · results posted	An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age Stealth BioTherapeutics Inc. · Age-Related Macular Degeneration	Completed
NCT02914665 Phase 2 · n=308 · 2016	A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Stealth BioTherapeutics Inc. · Heart Failure	Completed
NCT02814097 Phase 2 · n=46 · 2016	A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Hea Stealth BioTherapeutics Inc. · Chronic Heart Failure	Completed
NCT02805790 Phase 2 · n=30 · 2016 · results posted	Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study Stealth BioTherapeutics Inc. · Primary Mitochondrial Disease	Completed
NCT02788747 Phase 2 · n=71 · 2016 · results posted	Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction Stealth BioTherapeutics Inc. · Heart Failure	Completed
NCT02693119 Phase 2 · n=12 · 2016 · results posted	A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Stealth BioTherapeutics Inc. · Leber's Hereditary Optic Neuropathy	Completed
NCT02653391 Phase 1/Phase 2 · n=22 · 2016 · results posted	A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Stealth BioTherapeutics Inc. · Fuchs' Corneal Endothelial Dystrophy (FCED)	Completed
NCT02367014 Phase 1/Phase 2 · n=36 · 2015 · results posted	Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy Stealth BioTherapeutics Inc. · Mitochondrial Myopathy	Completed
NCT02245620 Phase 2 · n=41 · 2015 · results posted	A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly Stealth BioTherapeutics Inc. · Skeletal Muscle Mitochondrial Dysfunction in the Elderly	Completed
NCT01755858 Phase 1/Phase 2 · n=16 · 2012 · results posted	Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery Stealth BioTherapeutics Inc. · Renal Artery Obstruction, Hypertension, Renovascular	Terminated
NCT01572909 Phase 2 · n=300 · 2012 · results posted	Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events Stealth BioTherapeutics Inc. · Reperfusion Injury, STEMI	Completed
NCT04689360 n/a	An Intermediate Size Expanded Access Protocol of Elamipretide Stealth BioTherapeutics Inc. · Mitochondrial Diseases, Barth Syndrome	Available

epitalon: 1 registered trial

Trial	Title	Status
NCT07888595 Early Phase 1 · n=48 · 2026	Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks Frontiers in Bioscience Research Institute and Aging · Aging	Enrolling By Invitation

GHK-Cu: 24 registered trials

Trial	Title	Status
NCT07706361 n/a · n=100 · 2027	Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults LifeWave, Inc. · GHK and GHK-Cu Blood Levels	Not Yet Recruiting
NCT07888595 Early Phase 1 · n=48 · 2026	Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks Frontiers in Bioscience Research Institute and Aging · Aging	Enrolling By Invitation
NCT07688187 Phase 1 · n=60 · 2026	A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma PeptiDream Inc. · Clear Cell Renal Cell Carcinoma	Recruiting
NCT07879833 n/a · n=43 · 2025	AI-Personalized Skincare Regimen for Facial Photoaging in Women MDalgorithms Inc. · Photoaging, Skin Aging	Completed
NCT06522932 Phase 1 · n=32 · 2024	PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy Michael Randall · Non Hodgkin Lymphoma	Recruiting
NCT06379217 Phase 1 · n=31 · 2024	NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Pro Novartis Pharmaceuticals · Metastatic Neuroendocrine Prostate Cancer	Active Not Recruiting
NCT06016855 Phase 4 · n=6 · 2024	Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors Vanderbilt-Ingram Cancer Center · Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2	Recruiting
NCT05932732 Phase 4 · n=27 · 2023	Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Typ Austin Institute for Clinical Research · Cutis Laxa Facialis, Xeroderma	Completed
NCT06103617 Phase 2 · n=10 · 2023	Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer Nanfang Hospital, Southern Medical University · Head and Neck Cancer, Recurrent Cancer	Unknown
NCT05376878 Phase 4 · n=10 · 2022	An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis City of Hope Medical Center · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma	Recruiting
NCT04711135 Phase 2 · n=11 · 2022 · results posted	Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs Advanced Accelerator Applications · Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma	Active Not Recruiting
NCT05613842 Phase 2 · n=30 · 2022	Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP) St Vincent's Hospital, Sydney · Prostate Cancer	Completed
NCT05389813 Phase 2/Phase 3 · n=150 · 2021	Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia An-Najah National University · Anesthesia	Unknown
NCT07027670 Phase 2 · n=48 · 2021	Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery University of Oxford · Cardiac Surgical Procedures, Coronary Artery Bypass	Completed
NCT04542629 Phase 4 · n=140 · 2020	Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children Assiut University · Refractory Epilepsy	Unknown
NCT04023331 Phase 1/Phase 2 · n=21 · 2020	67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma Clarity Pharmaceuticals Ltd · Neuroblastoma, Relapsed Neuroblastoma	Terminated
NCT03936426 Phase 1/Phase 2 · n=5 · 2018	Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™ Clarity Pharmaceuticals Ltd · Meningioma	Completed
NCT02827877 Phase 2 · n=18 · 2018 · results posted	Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer City of Hope Medical Center · HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer	Active Not Recruiting
NCT07054697 Phase 4 · n=54 · 2017	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder Aditi Chadha · Autism Spectrum Disorder (ASD)	Completed
NCT06762509 n/a · n=60 · 2016	The Clinical Study of Botulinum Toxin Type A Injection in the Treatment of Wilson Disease The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine · Wilson Disease	Completed
NCT02226276 n/a · n=10 · 2015 · results posted	Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positi City of Hope Medical Center · Bone Metastases, HER2-positive Breast Cancer	Active Not Recruiting
NCT02125474 n/a · n=39 · 2013	Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate Instituto Nacional de Cancerologia, Columbia · Neuroendocrine Tumors	Completed
NCT00311298 Phase 3 · n=1250 · 2006	Nutrition, Diabetes and Pulmonary TB/HIV University of Copenhagen · Tuberculosis, HIV	Completed
NCT00003751 Phase 2 · n=40 · 1999	Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Brain and Central Nervous System Tumors	Completed

IGF-1 LR3: 0 registered trials

No registered trial names this peptide as an intervention (intervention search; a trial filed under another name or a combination product would not appear here).

ipamorelin: 3 registered trials

Trial	Title	Status
NCT07717866 n/a · n=52 · 2022	Trifecta Research Study Axial Therapeutic Research · PTSD – Post Traumatic Stress Disorder, Cognitive Dysfunction	Active Not Recruiting
NCT01280344 Phase 2 · n=320 · 2011	Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function Helsinn Therapeutics (U.S.), Inc · Gastrointestinal Dysmotility	Completed
NCT00672074 Phase 2 · n=117 · 2008	Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus Helsinn Therapeutics (U.S.), Inc · Ileus	Completed

Kisspeptin: 36 registered trials

Trial	Title	Status
NCT07224490 Phase 1 · n=40 · 2026	Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease Stephanie B. Seminara, MD · Reproductive Disorder, Neurodegeneration	Recruiting
NCT07224438 Phase 2 · n=20 · 2025	Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea Stephanie B. Seminara, MD · Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism	Recruiting
NCT06793098 n/a · n=100 · 2025	Functional Proteins in Polycystic Ovary Syndrome Jagiellonian University · Reproductive Age, PCOS (Polycystic Ovary Syndrome)	Recruiting
NCT06501729 n/a · n=33 · 2024	Kissing as a Protective Factor Against Acidic pH in Saliva Universidad Catolica Santiago de Guayaquil · Dental Caries, Tooth Demineralization	Completed
NCT06545994 n/a · n=180 · 2024	A Prospective Cohort Study on the Serum Kisspeptin Levels Throughout Pregnancy in PCOS Fudan University · Polycystic Ovary Syndrome, Pregnancy Complications	Unknown
NCT05901467 Phase 1 · n=16 · 2023 · results posted	Recall by Genotype: Neuropeptide Stimulation Stephanie B. Seminara, MD · Reproductive Disorder	Terminated
NCT05971849 Phase 1 · n=8 · 2023	Dampening the Reproductive Axis With Continuous Kisspeptin Stephanie B. Seminara, MD · Reproductive Disorder, PCOS	Completed
NCT05835089 n/a · n=50 · 2023	Evaluation of Some Puberty-related Hormones Among Children and Adolescents With Chronic Kidney Diseases Sohag University · Evaluation of Some Puberty-related Hormones Among Children and Adolescents With Chronic Kidney Diseases	Unknown
NCT05896293 Phase 2 · n=36 · 2023	Kisspeptin Administration Subcutaneously to Patients With IHH Stephanie B. Seminara, MD · Hypogonadotropic Hypogonadism	Recruiting
NCT05633966 Phase 1 · n=13 · 2022	Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders Stephanie B. Seminara, MD · Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism	Completed
NCT05456854 Phase 1 · 2022	Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp Massachusetts General Hospital · Metabolic Disease	Withdrawn
NCT04958109 Phase 1 · n=16 · 2021 · results posted	Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test Massachusetts General Hospital · Metabolic Diseases	Completed
NCT05971836 n/a · n=854 · 2021	The Molecular Basis of Inherited Reproductive Disorders Stephanie B. Seminara, MD · Hypogonadotropic Hypogonadism, Reproductive Disorder	Completed
NCT06775990 n/a · n=60 · 2020	Molecules Associated with Pediatric Obesity Istanbul University – Cerrahpasa · OBESITY	Completed
NCT03877939 n/a · n=433 · 2019	Detection of Kisspeptins and miRNAs in Patients With Non-viable Pregnancy Vida Recoletas Sevilla · Non-Viable Pregnancy	Completed
NCT04532801 Phase 1 · 2019	Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance Stephanie B. Seminara, MD · Insulin, Glucose	Withdrawn
NCT04648969 Phase 2 · n=18 · 2019 · results posted	Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism Stephanie B. Seminara, MD · Hypogonadotropic Hypogonadism	Completed
NCT03940495 n/a · n=182 · 2019	Serum Kisspeptin: a Predictive Marker of Miscarriage or Not? ShangHai Ji Ai Genetics & IVF Institute · Miscarriage	Completed
NCT04371991 n/a · n=88 · 2019	Kisspeptin Levels in Early Pregnancy Semra Yuksel · Early Pregnancy, Ectopic Pregnancy	Completed
NCT02956447 Phase 2 · n=36 · 2017 · results posted	Administration of Kisspeptin in Patients With Hyperprolactinemia Massachusetts General Hospital · Hyperprolactinemia, Hypogonadism	Completed
NCT04012632 n/a · n=628 · 2016	Kisspeptin/GPR54 Pathway and Early Puberty Shenzhen Center for Disease Control and Prevention · Puberty, Precocious	Completed
NCT03018314 n/a · n=90 · 2016	Serum Kisspeptin Levels in Infertile Women Bakirkoy Dr. Sadi Konuk Research and Training Hospital · Infertility, Female, Unexplained Infertility	Completed
NCT02381288 Phase 2 · n=17 · 2015 · results posted	Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone Takeda · Low Testosterone	Terminated
NCT02369796 Phase 2 · n=15 · 2015 · results posted	A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism Takeda · Hypogonadotropic Hypogonadism	Terminated
NCT03315325 Phase 3 · n=15 · 2014	Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men Quaid-e-Azam University · Sterility, Reproductive	Completed
NCT03286517 Phase 3 · n=30 · 2014	Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys. Ghulam Nabi · Reproductive Physiological Phenomena	Completed
NCT01952782 Phase 1 · n=61 · 2014	Neuropeptides in Human Reproduction Massachusetts General Hospital · Hypogonadotropic Hypogonadism	Completed
NCT02081924 n/a · n=76 · 2014	Reproductive Hormones During Sustained Administration of Kisspeptin Imperial College London · Fertility Disorders, Hypothalamic Dysfunction	Recruiting
NCT02877992 n/a · n=236 · 2014	Tachykinin and Kisspeptin Expression in Human Granulosa and Cumulus Cells Vida Recoletas Sevilla · Infertility	Completed
NCT03771326 Phase 3 · n=14 · 2013	KP-10 and Insulin Secretion in Men Quaid-e-Azam University · Kisspeptin Action on Insulin in Healthy Normal Men, Kisspeptin Action on Insulin in Obese Diabetic Men	Completed
NCT01956851 n/a · n=55 · 2013	Association of Kisspeptin Levels With Insulin Secretion in Diabetes Mellitus Ganga Care Hospital, Nagpur · Diabetes Mellitus	Completed
NCT01438034 Phase 1 · n=24 · 2013	Kisspeptin in the Evaluation of Delayed Puberty Massachusetts General Hospital · Delayed Puberty, Kallmann Syndrome	Completed
NCT01667406 Phase 2 · n=175 · 2012 · results posted	The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment Imperial College London · Infertility	Completed
NCT01438073 Phase 1 · n=96 · 2011	Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling Massachusetts General Hospital · Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women	Completed
NCT01132404 Phase 1/Phase 2 · n=9 · 2010	Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 Millennium Pharmaceuticals, Inc. · Prostate Cancer, Prostatic Neoplasms	Terminated
NCT00914823 Phase 1 · n=256 · 2009	Kisspeptin Administration in the Adult Massachusetts General Hospital · Hypogonadotropic Hypogonadism, Kallmann Syndrome	Completed

KPV: 0 registered trials

No registered trial names this peptide as an intervention (intervention search; a trial filed under another name or a combination product would not appear here).

liraglutide: 521 registered trials

Trial	Title	Status
NCT07787936 n/a · n=150 · 2027	GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry Miedziowe Centrum Zdrowia SA · Heart Failure With Preserved Ejection Fraction, Obesity	Not Yet Recruiting
NCT07929233 n/a · n=250 · 2027	24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor Portuguese Oncology Institute, Coimbra · Retained Gastric Content, Delayed Gastric Emptying	Not Yet Recruiting
NCT07027969 Phase 4 · n=100 · 2026	Metabolic Surgery for Atrial Fibrillation Elimination Ali Aminian · Atrial Fibrillation, Obesity and Obesity-related Medical Conditions	Not Yet Recruiting
NCT07881783 n/a · n=3718 · 2026	A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Novartis Pharmaceuticals · Plaque Psoriasis	Not Yet Recruiting
NCT07901777 n/a · n=200 · 2026	Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity Yuzuncu Yil University · Obesity & Overweight	Recruiting
NCT07702461 n/a · n=300 · 2026	Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists Ohio State University · Obesity & Overweight, Diabetes (DM)	Recruiting
NCT06726577 Phase 1/Phase 2 · n=60 · 2026	TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis Talengen Institute of Life Sciences, Shenzhen, P.R. China. · Amyotrophic Lateral Sclerosis	Recruiting
NCT07301437 Phase 4 · n=120 · 2026	RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Overweight and Obese Adults	Not Yet Recruiting
NCT07107334 Phase 2 · n=20 · 2026	A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device i University of Florida · Endometrioid Endometrial Adenocarcinoma	Recruiting
NCT06836284 n/a · n=40 · 2026	The Evira Study: Additional Support During Obesity Treatment Karolinska Institutet · Childhood Obesity, Treatment Adherence	Recruiting
NCT07640139 n/a · n=125000 · 2026	Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes Indiana University · Obesity	Enrolling By Invitation
NCT07225816 Phase 1 · n=71 · 2025	Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in Peop Novo Nordisk A/S · Obesity	Recruiting
NCT07907965 Phase 2 · n=15 · 2025	A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease Beijing University of Chinese Medicine · Diabetic Kidney Disease (DKD), Type 2 Diabetes	Active Not Recruiting
NCT06976619 Phase 2 · n=60 · 2025	The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes Mayo Clinic · Type 1 Diabetes, Type 2 Diabetes	Recruiting
NCT07188545 n/a · n=23280000 · 2025	Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (C Ohio State University · Cardiovascular Kidney Metabolic Syndrome	Active Not Recruiting
NCT07908940 n/a · n=116 · 2025	Changes in Body Composition Following Pharmacological Treatment for Obesity. Hospital San Carlos, Madrid · Obesity (BMI Equal to or >30), Weight Regain After Bariatric Surgery	Enrolling By Invitation
NCT06903923 Phase 2 · n=120 · 2025	Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy University of Virginia · Obesity in Children, Bone Strength	Recruiting
NCT07042672 n/a · n=80 · 2025	Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity Haukeland University Hospital · Binge Eating Disorder Associated With Obesity, Binge Eating Disorder	Recruiting
NCT07225829 Phase 2 · n=130 · 2025	A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis 4Moving Biotech · Knee Osteoarthritis, Synovitis of Knee	Completed
NCT07094568 n/a · n=72 · 2025	Tirzepatide vs Liraglutide in Bone National and Kapodistrian University of Athens · Obesity (Disorder)	Recruiting
NCT06742710 Phase 4 · n=890 · 2025	Liraglutide Treatment in Obese Infertile PCOS Women Peking University Third Hospital · PCOS, Obesity	Recruiting
NCT07029009 Phase 2 · n=50 · 2025	Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) Mansa · Maturity Onset Diabetes of the Young	Recruiting
NCT06865365 Phase 4 · n=72 · 2025	Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone Medical University of Vienna · Obesity, Adolescent	Not Yet Recruiting
NCT07244003 Phase 4 · n=430 · 2025	Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · T2DM (Type 2 Diabetes Mellitus)	Recruiting
NCT07325435 Phase 4 · n=60 · 2024	Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists MaryAnn Banerji · Type 2 Diabetes (T2DM)	Active Not Recruiting
NCT06361238 Phase 3 · n=260 · 2024	Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Delirium, Postoperative	Recruiting
NCT06818292 n/a · n=10 · 2024	Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists Nils Opel · Healthy	Completed
NCT06449235 Phase 4 · n=938 · 2024	Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · Type2diabetes	Unknown
NCT05965908 Phase 3 · n=183 · 2024	Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome Beni-Suef University · Polycystic Ovary	Completed
NCT06559722 Phase 3 · n=510 · 2024	A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes Tonghua Dongbao Pharmaceutical Co.,Ltd · Type 2 Diabetes	Unknown
NCT06533527 Phase 4 · n=69 · 2024 · results posted	Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy The Cleveland Clinic · Diabetes Mellitus, Type 2, Obesity	Completed
NCT06374875 Phase 4 · n=120 · 2024	Fibrosis Lessens After Metabolic Surgery The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease	Recruiting
NCT06581120 n/a · n=100 · 2024	GLP_1 RA Ultrasound Study Children's Hospital Medical Center, Cincinnati · Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying	Enrolling By Invitation
NCT06686134 n/a · n=492 · 2024	Comprehensive Clinical Evaluation Study of GLP-1RA LI YAN · T2DM	Recruiting
NCT06482411 n/a · n=3602 · 2024	Risk Factors Affect Weight Loss Outcomes After Treatment. E-DA Hospital · Weight Regain	Completed
NCT06720246 n/a · n=50 · 2024	Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Obesity and Overweight	Recruiting
NCT06500130 n/a · n=22 · 2024	Effects of Liraglutide on Body Surface Gastric Mapping Alimetry · Gastroparesis, Functional Dyspepsia	Completed
NCT06439056 Phase 1 · n=12 · 2024	Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D Nanexa AB · Type 2 Diabetes	Completed
NCT06925334 Phase 4 · n=170 · 2024	A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus Beijing Tsinghua Chang Gung Hospital · Type 2 Diabetic Patients	Enrolling By Invitation
NCT06400615 Phase 2 · n=40 · 2024	Study That Tests AD109 in Patients Taking GLP-1 Drugs Apnimed · OSA	Completed

Showing the 40 most recent of 521.

mazdutide: 45 registered trials

Trial	Title	Status
NCT07924553 n/a · n=182 · 2027	Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 Diabetes Peking University People's Hospital · Type 1 Diabetes	Not Yet Recruiting
NCT07803705 n/a · n=194 · 2026	Efficacy of Mazdutide on Fatty Pancreas Tongji Hospital · Fatty Pancreas, Overweight	Not Yet Recruiting
NCT07775846 Phase 4 · n=820 · 2026	QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy Huijie Zhang · Type 2 Diabetic Kidney Disease	Recruiting
NCT07781150 Phase 2 · n=128 · 2026	Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer Tongji Hospital · Obesity, Overweight	Not Yet Recruiting
NCT07897305 n/a · n=700 · 2026	Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients Beijing Anzhen Hospital · Atrial Fibrillation (AF), Ablation Treatment	Not Yet Recruiting
NCT07843862 Phase 2 · n=240 · 2026	A Study of HRS-4729 Injection in Participants With Type 2 Diabetes Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes	Not Yet Recruiting
NCT07767552 n/a · n=249 · 2026	Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial Yanbing Li · Diabetes Mellitus, Type 2	Not Yet Recruiting
NCT07824895 Phase 4 · n=30 · 2026	Mazdutide for Weight Management and Gout in Adults With Obesity Hongwei Jiang · Gout, Obesity (BMI>30)	Not Yet Recruiting
NCT07713992 n/a · n=72 · 2026	Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previousl Tianjin Medical University · Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus	Not Yet Recruiting
NCT07657676 Phase 4 · n=116 · 2026	Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity China National Center for Cardiovascular Diseases · Obesity & Overweight, Coronary Heart Disease	Recruiting
NCT07797101 n/a · n=50 · 2026	Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis The Second Affiliated Hospital of Chongqing Medical University · Cirrhosis, Portal Hypertension	Not Yet Recruiting
NCT07718126 Phase 4 · n=60 · 2026	Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) West China Hospital · Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis	Recruiting
NCT07654062 Phase 4 · n=150 · 2026	Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) Shandong Provincial Hospital · Prediabetes, Impaired Fasting Glucose	Not Yet Recruiting
NCT07517042 n/a · n=420 · 2026	ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management Shanghai Zhongshan Hospital · Obesity, Weight Control	Recruiting
NCT07633639 n/a · n=200 · 2026	GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity China-Japan Friendship Hospital · Obesity	Recruiting
NCT07469800 Phase 3 · n=336 · 2026	Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity Innovent Biologics (Suzhou) Co. Ltd. · Overweight, Obesity	Recruiting
NCT07417306 Phase 3 · n=912 · 2026	A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SG Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes	Not Yet Recruiting
NCT07255209 Phase 3 · n=180 · 2025	A Study of IBI362 in Chinese Adolescents With Obesity or Overweight Innovent Biologics (Suzhou) Co. Ltd. · Adolescents With Obesity or Overweight With Weight-Related Comorbidities	Recruiting
NCT07135141 n/a · n=256 · 2025	Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity Beijing Friendship Hospital · Severe Obesity	Not Yet Recruiting
NCT07083154 Phase 3 · n=420 · 2025	Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Dementia, Mild, Mild Cognitive Impairment	Recruiting
NCT06937749 Phase 2 · n=181 · 2025	A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Innovent Biologics (Suzhou) Co. Ltd. · Metabolic Dysfunction-associated Steatohepatitis (MASH)	Active Not Recruiting
NCT07000955 Phase 1/Phase 2 · n=98 · 2025	Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity Innovent Biologics (Suzhou) Co. Ltd. · Obesity	Active Not Recruiting
NCT06931028 Phase 3 · n=260 · 2025	A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 Innovent Biologics (Suzhou) Co. Ltd. · Sleep Apnea, Obstructive	Recruiting
NCT06884293 Phase 3 · n=479 · 2025	A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAF Innovent Biologics (Suzhou) Co. Ltd. · Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)	Active Not Recruiting
NCT06862908 Phase 2 · n=141 · 2025	A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF)	Active Not Recruiting
NCT06817356 Phase 2 · n=308 · 2025	A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder Eli Lilly and Company · Alcohol Use Disorder	Completed
NCT06519656 Phase 1/Phase 2 · n=43 · 2024	Efficacy of Mazdutide for Treating PCOS Shanghai Zhongshan Hospital · Polycystic Ovary Syndrome	Completed
NCT06536023 Phase 1 · n=36 · 2024	This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity Innovent Biologics (Suzhou) Co. Ltd. · Adolescents With Obesity	Completed
NCT06184568 Phase 3 · n=349 · 2024	A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes, Obesity	Completed
NCT06164873 Phase 3 · n=462 · 2023	A Study of IBI362 9 mg in Chinese Adults With Obesity Innovent Biologics (Suzhou) Co. Ltd. · Obesity	Unknown
NCT06143956 Phase 2 · n=1481 · 2023	A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight Eli Lilly and Company · Obesity, Overweight	Recruiting
NCT06124807 Phase 2 · n=179 · 2023 · results posted	A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight Eli Lilly and Company · Obesity, Overweight and Obesity	Completed
NCT05793450 Phase 1 · n=20 · 2023	Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment Innovent Biologics (Suzhou) Co. Ltd. · Renal Impairment	Completed
NCT05815680 Phase 1 · n=48 · 2023	A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subje Innovent Biologics (Suzhou) Co. Ltd. · Overweight Subjects, Obese Subjects	Completed
NCT05628311 Phase 3 · n=319 · 2023	A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes	Completed
NCT05606913 Phase 3 · n=731 · 2023	A Study of IBI362 in Participants With Type 2 Diabetes Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes	Completed
NCT05623839 Phase 1 · n=32 · 2022	A Study of LY3305677 in Participants With Obesity Or Overweight Eli Lilly and Company · Overweight, Obesity	Completed
NCT05607680 Phase 3 · n=610 · 2022	A Study of IBI362 in Participants With Obesity or Overweight Innovent Biologics (Suzhou) Co. Ltd. · Obesity Or Overweight	Completed
NCT04965506 Phase 2 · n=252 · 2021	A Study of IBI362 in Chinese Patients With Type 2 Diabetes Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes	Completed
NCT04904913 Phase 2 · n=328 · 2021	A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects Innovent Biologics (Suzhou) Co. Ltd. · Overweight/ Obesity	Completed

Showing the 40 most recent of 45.

melanotan II: 23 registered trials

Trial	Title	Status
NCT06388642 Phase 1/Phase 2 · n=28 · 2024 · results posted	Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients Clinuvel Europe Limited · Erythropoietic Protoporphyria	Completed
NCT06109649 Phase 3 · n=200 · 2023	A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Clinuvel, Inc. · Vitiligo	Active Not Recruiting
NCT05854784 Phase 2 · n=6 · 2023 · results posted	Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP) Clinuvel Pharmaceuticals Limited · Variegate Porphyria	Completed
NCT05210582 Phase 2 · n=6 · 2022	A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face Clinuvel, Inc. · Vitiligo	Unknown
NCT05370235 Phase 2 · n=6 · 2022	A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V Clinuvel Europe Limited · Xeroderma Pigmentosum	Unknown
NCT05368857 Phase 1 · n=10 · 2022	DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers Clinuvel (UK) Ltd. · Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers	Completed
NCT05159752 Phase 2 · n=6 · 2021	A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP) Clinuvel Europe Limited · Xeroderma Pigmentosum	Unknown
NCT04962503 Phase 2 · n=6 · 2021 · results posted	A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS) Clinuvel Pharmaceuticals Limited · Arterial Ischemic Stroke	Completed
NCT04525157 Phase 2 · n=21 · 2014 · results posted	Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV) Clinuvel Pharmaceuticals Limited · Vitiligo	Completed
NCT01605136 Phase 3 · n=93 · 2012 · results posted	Phase III Confirmatory Study in Erythropoietic Protoporphyria Clinuvel Pharmaceuticals Limited · Erythropoietic Protoporphyria	Completed
NCT01382589 Phase 2 · n=15 · 2011	Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Clinuvel Pharmaceuticals Limited · Vitiligo	Completed
NCT04578496 Phase 3 · n=16 · 2011 · results posted	A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP) Clinuvel Pharmaceuticals Limited · Erythropoietic Protoporphyria	Completed
NCT01430195 Phase 1 · n=56 · 2011	Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV) Clinuvel Pharmaceuticals Limited · Vitiligo	Completed
NCT04943159 Phase 2 · n=3 · 2010 · results posted	Afamelanotide in Patients Suffering With Acne Vulgaris Clinuvel Pharmaceuticals Limited · Acne Vulgaris	Completed
NCT04704713 Phase 3 · n=31 · 2010 · results posted	Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE) Clinuvel Pharmaceuticals Limited · Polymorphic Light Eruption	Completed
NCT01097044 Phase 2 · n=77 · 2010 · results posted	Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) Clinuvel Pharmaceuticals Limited · Erythropoietic Protoporphyria	Completed
NCT03634137 Phase 1 · n=24 · 2009	Implant Pharmacokinetic and Pharmacodynamic Study Clinuvel Pharmaceuticals Limited · Healthy	Completed
NCT00979745 Phase 3 · n=74 · 2009 · results posted	Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP) Clinuvel Pharmaceuticals Limited · Erythropoietic Protoporphyria	Completed
NCT00859534 Phase 2 · n=5 · 2008	Phase II Solar Urticaria (SU) Pilot Study Clinuvel Pharmaceuticals Limited · Solar Urticaria	Completed
NCT04425746 Phase 2 · n=16 · 2008 · results posted	Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium Clinuvel Pharmaceuticals Limited · Patients Undergoing Photodynamic Therapy Using Porfimer Sodium	Completed
NCT00829192 Phase 2 · n=200 · 2007	Phase II AK Study in Organ Transplant Patients Clinuvel Pharmaceuticals Limited · Actinic Keratoses, Carcinoma, Squamous Cell	Unknown
NCT04053270 Phase 3 · n=100 · 2007 · results posted	Multicentre Phase III Erythropoietic Protoporphyria Study Clinuvel Pharmaceuticals Limited · Erythropoietic Protoporphyria	Completed
NCT00472901 n/a · n=18 · 2007	Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE) Clinuvel Pharmaceuticals Limited · Polymorphic Light Eruption (PLE)	Completed

MOTS-c: 4 registered trials

Trial	Title	Status
NCT07678073 n/a · n=68 · 2026	Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal T University of Gaziantep · Kidney Disease, End-Stage, Kidney Transplant	Recruiting
NCT03878706 n/a · n=240 · 2017	The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination University of Athens · Diabetes Mellitus, Type 2	Recruiting
NCT06133946 n/a · n=35920 · 2016	Cohort Of DEafness-gene Screening Affiliated Hospital of Nantong University · Hearing Loss	Active Not Recruiting
NCT04027712 n/a · n=120 · 2014	Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD University of Athens · Diabetes, Clopidogrel Resistance	Unknown

Nisotirostide: 0 registered trials

No registered trial names this peptide as an intervention (intervention search; a trial filed under another name or a combination product would not appear here).

orforglipron: 53 registered trials

Trial	Title	Status
NCT07790861 Phase 3 · n=192 · 2026	A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems Eli Lilly and Company · Obesity, Overweight	Not Yet Recruiting
NCT07729332 Phase 4 · n=60 · 2026	Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation Massachusetts General Hospital · Obesity	Not Yet Recruiting
NCT07739537 Phase 4 · n=100 · 2026	PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses Massachusetts General Hospital · Diabete Type 2, Pharmacogenomic Drug Interaction	Not Yet Recruiting
NCT07793019 Phase 1 · n=104 · 2026	IBI3042 Study in Healthy Participants and Overweight or Obese Participants Innovent Biologics (Suzhou) Co. Ltd. · Overweight, Healthy Participants	Recruiting
NCT07794579 Phase 3 · n=2001 · 2026	A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Ob Eli Lilly and Company · Overweight, Prediabetic State	Recruiting
NCT07613307 Phase 3 · n=130 · 2026	A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting Eli Lilly and Company · Diabetes Mellitus, Type 2, Diabetes Melletus	Recruiting
NCT07668336 Phase 3 · n=170 · 2026	A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes Eli Lilly and Company · Diabetes Mellitus, Type 2	Recruiting
NCT07107334 Phase 2 · n=20 · 2026	A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device i University of Florida · Endometrioid Endometrial Adenocarcinoma	Recruiting
NCT07241390 Phase 3 · n=7140 · 2025	A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D Eli Lilly and Company · Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease	Recruiting
NCT07223593 Phase 3 · n=1205 · 2025	Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease Eli Lilly and Company · Peripheral Arterial Disease	Recruiting
NCT07202884 Phase 3 · n=1000 · 2025	A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight Eli Lilly and Company · Urinary Incontinence,Stress	Recruiting
NCT07153471 Phase 3 · n=800 · 2025	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee Eli Lilly and Company · Osteoarthritis	Active Not Recruiting
NCT06972472 Phase 3 · n=600 · 2025	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes Eli Lilly and Company · Obesity, Overweight	Active Not Recruiting
NCT06993792 Phase 3 · n=1400 · 2025	A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes Eli Lilly and Company · Obesity, Overweight	Active Not Recruiting
NCT06972459 Phase 3 · n=800 · 2025	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity Eli Lilly and Company · Obesity, Overweight	Active Not Recruiting
NCT06952530 Phase 3 · n=487 · 2025	A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 Eli Lilly and Company · Hypertension	Active Not Recruiting
NCT06948435 Phase 3 · n=487 · 2025	A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 Eli Lilly and Company · Hypertension, Overweight or Obesity	Active Not Recruiting
NCT06948422 Phase 3 · n=974 · 2025	A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) Eli Lilly and Company · Hypertension	Active Not Recruiting
NCT06824051 Phase 1 · n=120 · 2025	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight Eli Lilly and Company · Obesity, Overweight	Completed
NCT06692348 Phase 1 · n=86 · 2024	A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants Eli Lilly and Company · Healthy	Completed
NCT06704763 Phase 1 · n=27 · 2024 · results posted	A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants Eli Lilly and Company · Healthy	Completed
NCT06672939 Phase 3 · n=150 · 2024	A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities Eli Lilly and Company · Obesity, Overweight	Recruiting
NCT06672549 Phase 3 · n=125 · 2024	A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) Eli Lilly and Company · Obesity, Overweight	Recruiting
NCT06649045 Phase 3 · n=712 · 2024	A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight Eli Lilly and Company · OSA, Overweight or Obesity	Completed
NCT06584916 Phase 3 · n=376 · 2024	A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Como Eli Lilly and Company · Obesity, Overweight	Completed
NCT06440980 Phase 1 · n=533 · 2024 · results posted	A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight Eli Lilly and Company · Healthy, Obese	Completed
NCT06370728 Phase 1 · n=30 · 2024 · results posted	A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants Eli Lilly and Company · Healthy	Completed
NCT06192108 Phase 3 · n=962 · 2024 · results posted	A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W Eli Lilly and Company · Type 2 Diabetes	Completed
NCT06186622 Phase 1 · n=50 · 2024 · results posted	A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants Eli Lilly and Company · Healthy, Obese	Completed
NCT06109311 Phase 3 · n=546 · 2023 · results posted	A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or With Eli Lilly and Company · Type 2 Diabetes	Completed
NCT06085482 Phase 1 · n=10 · 2023 · results posted	A Phase I Study of LY3502970 in Healthy Participants Eli Lilly and Company · Healthy	Completed
NCT06010004 Phase 3 · n=401 · 2023 · results posted	A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Eli Lilly and Company · Type 2 Diabetes	Completed
NCT06045221 Phase 3 · n=1698 · 2023 · results posted	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin Eli Lilly and Company · Type 2 Diabetes	Completed
NCT06023095 Phase 1 · n=24 · 2023 · results posted	A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities Eli Lilly and Company · Overweight, Obesity	Completed
NCT05971940 Phase 3 · n=559 · 2023 · results posted	A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone Eli Lilly and Company · Type 2 Diabetes	Completed
NCT05931380 Phase 3 · n=238 · 2023 · results posted	A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease Eli Lilly and Company · Obesity	Completed
NCT05936138 Phase 1 · n=24 · 2023 · results posted	A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants W Eli Lilly and Company · Renal Insufficiency, Healthy	Completed
NCT05882032 Phase 1 · n=29 · 2023 · results posted	A Study of LY3502970 in Participants With Impaired and Normal Liver Function Eli Lilly and Company · Healthy, Hepatic Insufficiency	Completed
NCT05872620 Phase 3 · n=1613 · 2023 · results posted	A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes Eli Lilly and Company · Obesity, Overweight	Completed
NCT05869903 Phase 3 · n=3127 · 2023 · results posted	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities Eli Lilly and Company · Obesity, Overweight	Active Not Recruiting

Showing the 40 most recent of 53.

oxytocin: 938 registered trials

Trial	Title	Status
NCT07902752 Phase 2 · n=100 · 2027	Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs George Washington University · Obesity & Overweight, Respiratory Depression	Not Yet Recruiting
NCT07492186 n/a · n=280 · 2027	3-hour Versus 12-hour Double-balloon Catheter for Labor Induction Centre Hospitalier de PAU · Induction of Childbirth	Not Yet Recruiting
NCT06364228 Phase 2 · n=32 · 2026	Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia University of Nebraska · Stress	Recruiting
NCT07922083 n/a · n=120 · 2026	Comparison of Effect of Two Different Doses of Intravenous Oxytocin on Patients Undergoing Elective Cesarean Section Shalamar Hospital · Postpartum Hemorrhage, Uterine Atony	Not Yet Recruiting
NCT07765992 n/a · n=76 · 2026	AI-Based Oxytocin-Stimulated Smart Lactation Support Vest Selcuk University · Lactation, Lactation Disorder – Postpartum Condition or Complication	Not Yet Recruiting
NCT06987786 n/a · n=25 · 2026	Differences in Mechanistic Measures (Oxytocin and Cortisol) of Therapeutic Alliance Between A Talk-Based Therapy and Soft-Tissue Mobilizatio Duke University · Spine, Low Back Pain	Not Yet Recruiting
NCT07770945 n/a · n=74 · 2026	Effects of Connective Tissue Massage in Patients With Chronic Insomnia Saglik Bilimleri Universitesi · Chronic Insomnia	Not Yet Recruiting
NCT07430228 Phase 2 · n=80 · 2026	Efficacy of Intravenous Oxytocin to Speed Recovery After THA Wake Forest University Health Sciences · Total Hip Arthroplasty	Enrolling By Invitation
NCT07832032 n/a · n=60 · 2026	Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine Nordlandssykehuset HF · Migraine	Enrolling By Invitation
NCT07873814 n/a · n=120 · 2026	Effect of Dural Puncture Epidural Analgesia on Oxytocin in Early vs Late Labor Ankara City Hospital Bilkent · Labor Analgesia, Labor Pain	Not Yet Recruiting
NCT07867054 n/a · n=136 · 2026	Effects of Maternal and Infant Massage on Breastfeeding and Mother-Infant Bonding Istanbul University – Cerrahpasa · Breastfeeding, Mother-Infant Bonding	Not Yet Recruiting
NCT07730294 Phase 2 · n=75 · 2026	Evaluating Intranasal Oxytocin (TNX-1900) for Pain Relief and Recovery After Pituitary Surgery Yale University · Pain, Pituitary Surgery	Recruiting
NCT07874243 n/a · n=144 · 2026	Effect of a Vertical Birthing Chair on Labor Kartal City Hospital · Labor and Delivery	Not Yet Recruiting
NCT06710964 n/a · 2026	Inducing Self-Dehumanization to Examine Oxytocin and Suicide Risk Florida State University · Mechanistic Self-Dehumanization Condition, Control Condition	Withdrawn
NCT07838493 n/a · n=120 · 2026	Oromucosal Oxytocin and Vasopressin Modulation of Emotional Face Attention University of Electronic Science and Technology of China · Healhty	Recruiting
NCT07815496 n/a · n=80 · 2026	The Effects of Oxytocin on Fairness Perception and Related Prosocial Behaviors University of Electronic Science and Technology of China · Healthy Adult Participants	Recruiting
NCT07784478 n/a · n=60 · 2026	Effect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia Khyber Girls Medical College · Cesarean Section, Hypotension	Not Yet Recruiting
NCT07853924 Phase 4 · n=100 · 2026	Effect of Intravenous Oxytocin on Post Dural Puncture Headache After Caesarean Sections Assiut University · Post Dural Puncture Headache	Not Yet Recruiting
NCT07742124 n/a · n=30 · 2026	Oxytocin in Postmenopausal Women University Hospital, Basel, Switzerland · Postmenopausal, Premenopausal	Recruiting
NCT07717502 n/a · n=260 · 2026	Ripening Approaches for Prompt Induction and Delivery – Sequential Versus Concurrent Dilapan-S and Misoprostol to Achieve Vaginal Delivery ( Ochsner Health System · Nulliparous Women Who Scheduled for Labor Induction, Pregnancy	Recruiting
NCT06638450 n/a · n=148 · 2026	Clinical Trial for Acupuncture in Adolescents With Psychological Distress and Insomnia The University of Hong Kong · Psychological Distress, Insomnia	Recruiting
NCT07568509 Early Phase 1 · n=20 · 2026	Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease Massachusetts General Hospital · Arginine Vasopressin Deficiency, Oxytocin Deficiency	Recruiting
NCT07636421 Phase 4 · n=332 · 2026	Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial Mansoura University · Postpartum Hemorrhage, Uterine Atony	Recruiting
NCT07781189 n/a · n=164 · 2026	Trial of Ultrasound-guided Rotation for Normalizing Head Position Anhui Provincial Hospital · Abnormal Fetal Head Position	Not Yet Recruiting
NCT07688512 Phase 4 · n=180 · 2026	Oxytocin Bolus Versus Infusion in High-Risk Patients Undergoing Elective Cesarean Section (INBOX-HR) Stony Brook University · Postpartum Hemorrhage, Uterine Atony	Not Yet Recruiting
NCT06713473 n/a · 2026	Reducing Self-Dehumanization to Examine Oxytocin and Suicide Risk Florida State University · Rehumanization Intervention, Control Intervention	Withdrawn
NCT07214948 n/a · n=12 · 2026	Open, Randomized Feasibility Trial on the Safety and Performance of the INGA Catheter for Labor Induction Aalto University · Induction of Birth, Cervical Ripening	Terminated
NCT07687355 n/a · n=262 · 2026	Compare Hemodynamic Effect of Oxytocin Bolus and Infusion During Cesarean Section Under Spinal Anesthesia Hayatabad Medical Complex · Comparing 2 Techniques of iv Oxytocin Causing Hemodynamic Changes	Not Yet Recruiting
NCT07588529 n/a · n=48 · 2026	Is Nipple Stimulation Effective for Inducing Labor and Acceptable to Patients, Nurses, and Providers? University of Kansas Medical Center · Pregnancy, Induction of Labor	Not Yet Recruiting
NCT07507266 n/a · n=60 · 2026	Emotions From Salivary Biomarkers in an Architectural Context Sys2Diag · Emotions	Not Yet Recruiting
NCT07615530 n/a · n=51 · 2026	Positive Expectation Effects on Early Emotional Processing Universitätsklinikum Hamburg-Eppendorf · Positive Expectations	Not Yet Recruiting
NCT07555132 n/a · n=40 · 2026	Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls University Hospital, Basel, Switzerland · Autism Spectrum Disorder	Not Yet Recruiting
NCT06968481 Phase 2 · n=330 · 2026	Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage Insud Pharma · Post Partum Hemorrhage	Not Yet Recruiting
NCT07609693 n/a · n=128 · 2026	The Relationship Between Oxytocin Massage in Mothers With Insufficient Milk Production in the Early Postpartum Period and Breastfeeding Self Tokat Gaziosmanpasa University · Lactation Disorders	Recruiting
NCT07401524 Phase 4 · n=120 · 2026	Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage Sheba Medical Center · Postpartum Hemorrhage, Twin Pregnancy	Recruiting
NCT07550413 Phase 2 · n=182 · 2026	Role of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section Pak Emirates Military Hospital · Post Partum Haemorrhage, Cesarean Section Surgery	Not Yet Recruiting
NCT07559656 n/a · n=80 · 2026	Oxytocin's Effects on Real Time-fMRI Neurofeedback Training of Anterior Insula Activity University of Electronic Science and Technology of China · Healthy	Recruiting
NCT07544355 n/a · n=93 · 2026	A Mindfulness-Based Stress Reduction Training Program Model Istanbul Medeniyet University · Depression, Anxiety	Recruiting
NCT07401160 n/a · n=400 · 2026	Umbilical Cord Drainage to Prevent Postpartum Hemorrhage Universidad Nacional Autonoma de Honduras · Postpartum Hemorrhage	Recruiting
NCT07420127 Phase 4 · n=112 · 2026	Comparison of Two Different Doses of Phenylephrine on Oxytocin Hemodynamic Effect Rawalpindi Medical College · Phenylephrine, Cesarean Birth	Recruiting

Showing the 40 most recent of 938.

Pinealon: 0 registered trials

No registered trial names this peptide as an intervention (intervention search; a trial filed under another name or a combination product would not appear here).

retatrutide: 33 registered trials

Trial	Title	Status
NCT07357415 Phase 3 · n=600 · 2026	A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight Eli Lilly and Company · Obesity, Overweight	Active Not Recruiting
NCT07232719 Phase 3 · n=250 · 2025	A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight Eli Lilly and Company · Obesity, Overweight	Active Not Recruiting
NCT07165028 Phase 3 · n=4500 · 2025	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Eli Lilly and Company · Metabolic Dysfunction-Associated Steatotic Liver Disease	Recruiting
NCT06982846 Phase 1 · n=80 · 2025	A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia Eli Lilly and Company · Type 2 Diabetes Mellitus	Completed
NCT06982859 Phase 1 · n=95 · 2025	A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellit Eli Lilly and Company · Diabetes Mellitus, Insulin Sensitivity	Active Not Recruiting
NCT07035093 Phase 3 · n=586 · 2025	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain Eli Lilly and Company · Obesity, Overweight	Active Not Recruiting
NCT06859268 Phase 3 · n=643 · 2025	A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Eli Lilly and Company · Obesity	Active Not Recruiting
NCT06808802 Phase 1 · n=30 · 2025	To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants Eli Lilly and Company · Healthy	Completed
NCT06662383 Phase 3 · n=800 · 2024	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity Eli Lilly and Company · Obesity	Active Not Recruiting
NCT06383390 Phase 3 · n=10000 · 2024	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Eli Lilly and Company · Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	Active Not Recruiting
NCT06354660 Phase 3 · n=537 · 2024	Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercis Eli Lilly and Company · Diabetes Type 2	Completed
NCT06313528 Phase 1 · n=85 · 2024	A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 Eli Lilly and Company · Obesity	Completed
NCT06297603 Phase 3 · n=320 · 2024	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Gl Eli Lilly and Company · Type 2 Diabetes	Active Not Recruiting
NCT06260722 Phase 3 · n=1250 · 2024	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin Wi Eli Lilly and Company · Diabetes Mellitus, Type 2	Active Not Recruiting
NCT06039826 Phase 1 · n=46 · 2023	A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese Eli Lilly and Company · Overweight	Completed
NCT06003465 Phase 1 · n=57 · 2023	A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices Eli Lilly and Company · Healthy	Completed
NCT05931367 Phase 3 · n=445 · 2023	A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee Eli Lilly and Company · Obesity, Overweight	Completed
NCT05936151 Phase 2 · n=146 · 2023 · results posted	A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without T Eli Lilly and Company · Overweight or Obesity, CKD	Completed
NCT05959096 Phase 1 · n=85 · 2023	A Study of LY3437943 in Healthy Participants With a High Body Mass Index Eli Lilly and Company · Healthy	Completed
NCT05916560 Phase 1 · n=43 · 2023	A Study of LY3437943 in Participants With Impaired and Normal Liver Function Eli Lilly and Company · Healthy, Hepatic Insufficiency	Completed
NCT05929079 Phase 3 · n=1152 · 2023	A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight Eli Lilly and Company · Type 2 Diabetes, Obesity	Completed
NCT05929066 Phase 3 · n=2335 · 2023	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight Eli Lilly and Company · Obesity, Overweight	Completed
NCT05882045 Phase 3 · n=1946 · 2023	A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease Eli Lilly and Company · Obesity, Cardiovascular Diseases	Completed
NCT05757531 Phase 1 · n=7 · 2023	A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants Eli Lilly and Company · Healthy	Completed
NCT05611957 Phase 1 · n=29 · 2022	A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function Eli Lilly and Company · Healthy, Renal Insufficiency	Completed
NCT05548231 Phase 1 · n=32 · 2022	A Study of LY3437943 in Chinese Participants With Obesity Or Overweight Eli Lilly and Company · Overweight, Obesity	Completed
NCT05445232 Phase 1 · n=32 · 2022	A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants Eli Lilly and Company · Obesity	Completed
NCT04823208 Phase 1 · n=64 · 2021	A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) Eli Lilly and Company · Diabetes Mellitus, Type 2	Completed
NCT04881760 Phase 2 · n=338 · 2021 · results posted	A Study of LY3437943 in Participants Who Have Obesity or Are Overweight Eli Lilly and Company · Obesity, Overweight	Completed
NCT04867785 Phase 2 · n=281 · 2021 · results posted	A Study of LY3437943 in Participants With Type 2 Diabetes Eli Lilly and Company · Type 2 Diabetes	Completed
NCT04143802 Phase 1 · n=72 · 2019	A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) Eli Lilly and Company · Diabetes Mellitus, Type 2	Completed
NCT03841630 Phase 1 · n=45 · 2019	A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants Eli Lilly and Company · Healthy	Completed
NCT07629401 n/a	Pre-approval Expanded Access of Retatrutide (LY3437943) Eli Lilly and Company · Obesity, Obesity-related Complications	Available

Selank: 2 registered trials

Trial	Title	Status
NCT05832060 n/a · n=24 · 2023	Comparing the Efficacy of tDCS and tRNS to Improve Reading Skills in Children and Adolescents With Dyslexia Bambino Gesù Hospital and Research Institute · Developmental Dyslexia	Unknown
NCT01747200 n/a · n=13 · 2012	Effects of Transcranial Magnetic Stimulation on Object Recognition National Institute of Neurological Disorders and Stroke (NINDS) · Repetitive TMS (rTMS), Sham rTMS	Completed

semaglutide: 802 registered trials

Trial	Title	Status
NCT07586150 n/a · n=140 · 2028	Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN) Ludwig-Maximilians – University of Munich · Severe Mental Illness, Depression / Major Depressive Disorder	Not Yet Recruiting
NCT07797036 Phase 2/Phase 3 · n=226 · 2027	Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus University of Massachusetts, Worcester · Gestational Diabetes Mellitus (GDM), Metabolic Syndrome	Not Yet Recruiting
NCT07430332 Phase 2 · n=15 · 2027	GLP-1 RA for Stage 1 Type 1 Diabetes Children's Hospital Medical Center, Cincinnati · Stage 1 Diabetes Mellitus, Type 1	Not Yet Recruiting
NCT07911046 n/a · n=12 · 2027	Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity Erin Mauney · Pediatric Obesity, Obesity	Not Yet Recruiting
NCT07909889 Phase 2 · n=32 · 2027	Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer Aarhus University Hospital · Breast Cancer (Early Breast Cancer), Obesity	Not Yet Recruiting
NCT07711548 n/a · n=292 · 2027	Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity? Knut Mai · Obesity & Overweight, Weight Loss Maintenance	Not Yet Recruiting
NCT07754045 Phase 2 · n=202 · 2027	Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults Lumos Pharma · Obesity & Overweight	Not Yet Recruiting
NCT07926152 n/a · n=94 · 2027	Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes German Diabetes Center · Type 2 Diabetes (T2DM), Obesity & Overweight	Not Yet Recruiting
NCT07731256 Phase 2 · n=250 · 2027	Semaglutide for Low Back Pain Washington University School of Medicine · Lower Back Pain, Obesity (BMI>30)	Not Yet Recruiting
NCT05714683 n/a · n=600 · 2027	Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Typ Novo Nordisk A/S · Diabetes Mellitus, Type 2	Not Yet Recruiting
NCT07879612 Phase 2 · n=40 · 2027	Semaglutide for the Treatment of Cannabis Use Disorder Massachusetts General Hospital · Cannabis Use Disorder, Cue-reactivity	Not Yet Recruiting
NCT07858331 Phase 4 · n=880 · 2027	Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access Kristin Clemens · Obesity, Chronic Kidney Disease	Not Yet Recruiting
NCT07820358 Phase 2 · n=48 · 2027	Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer The Methodist Hospital Research Institute · Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia	Not Yet Recruiting
NCT07787936 n/a · n=150 · 2027	GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry Miedziowe Centrum Zdrowia SA · Heart Failure With Preserved Ejection Fraction, Obesity	Not Yet Recruiting
NCT07614412 Phase 2 · n=240 · 2027	SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. Ministry of Health, Saudi Arabia · Type 1 Diabetes Mellitus	Not Yet Recruiting
NCT07929233 n/a · n=250 · 2027	24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor Portuguese Oncology Institute, Coimbra · Retained Gastric Content, Delayed Gastric Emptying	Not Yet Recruiting
NCT07923630 Phase 2 · n=1200 · 2027	Validation & Intervention Testing for Aging, Longevity and Healthspan The University of Texas Health Science Center at San Antonio · Aging, Functional Decline	Not Yet Recruiting
NCT07462663 Phase 4 · n=80 · 2027	SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Hospital Universitari de Bellvitge · Endometrial Cancer, Endometrial Cancer Stage I	Not Yet Recruiting
NCT06913023 Phase 2/Phase 3 · n=37 · 2026	Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus University Health Network, Toronto · Kidney Transplant Recipient	Not Yet Recruiting
NCT07770282 Phase 3 · n=600 · 2026	Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome All India Institute of Medical Sciences, Bhubaneswar · Schizophrenia Disorder, Metabolic Syndrome	Not Yet Recruiting
NCT07760948 Phase 2 · n=90 · 2026	HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide Vanderbilt University Medical Center · Type 2 Diabetes Mellitus (T2DM), Sarcopenia	Not Yet Recruiting
NCT07832084 Phase 4 · n=60 · 2026	Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s Jing Luo · Obesity & Overweight, Cardiometabolic Health Indicators	Not Yet Recruiting
NCT06977438 Phase 4 · n=1020 · 2026	GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward University of Minnesota · Obesity, Childhood	Not Yet Recruiting
NCT07919405 Phase 3 · n=1408 · 2026	A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obe Novo Nordisk A/S · Hypertension, Obesity	Not Yet Recruiting
NCT07855900 Phase 3 · n=350 · 2026	SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weig Boehringer Ingelheim · Obesity	Not Yet Recruiting
NCT07878494 n/a · n=30 · 2026	Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia Stanford University · Post-Bariatric Hypoglycemia	Not Yet Recruiting
NCT07027969 Phase 4 · n=100 · 2026	Metabolic Surgery for Atrial Fibrillation Elimination Ali Aminian · Atrial Fibrillation, Obesity and Obesity-related Medical Conditions	Not Yet Recruiting
NCT06546384 n/a · n=64 · 2026	GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease Insel Gruppe AG, University Hospital Bern · Adiposity, Fatty Liver	Not Yet Recruiting
NCT07845994 Phase 3 · n=50 · 2026	SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Seco University Hospital, Angers · Craniopharyngioma, Child	Not Yet Recruiting
NCT07249554 Phase 2 · n=45 · 2026	Combination Therapy for Alcohol Use Disorder Johns Hopkins University · Alcohol Use Disorder	Not Yet Recruiting
NCT07900074 Phase 4 · n=80 · 2026	Mechanisms of Weight Loss: Tirzepatide vs Semaglutide McMaster University · Obesity (Disorder)	Recruiting
NCT07511543 Phase 2 · n=100 · 2026	Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy Population Health Research Institute · Ischemic Stroke	Not Yet Recruiting
NCT07923357 Phase 2 · n=364 · 2026	A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus Shenzhen Salubris Pharmaceuticals Co., Ltd. · Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes	Not Yet Recruiting
NCT07881783 n/a · n=3718 · 2026	A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Novartis Pharmaceuticals · Plaque Psoriasis	Not Yet Recruiting
NCT07592546 Phase 4 · n=240 · 2026	Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss Alain Dagher · Class I/II Obesity	Recruiting
NCT07840729 Phase 1 · n=90 · 2026	Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants Shanghai JMT-Bio Inc. · Valid MeSH Conditiongs	Recruiting
NCT07770152 Phase 4 · n=42 · 2026	Semaglutide in Youth With Autism Spectrum Disorder Children's Hospital Medical Center, Cincinnati · Autism Spectrum Disorder, Obesity	Recruiting
NCT07866066 Phase 3 · n=1300 · 2026	Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes Amgen · Diabetes Mellitus, Type 2	Recruiting
NCT07889453 n/a · n=650 · 2026	Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide LMC Diabetes & Endocrinology Ltd. · Obesity, Type 2 Diabetes (T2D)	Active Not Recruiting
NCT07874971 n/a · n=41 · 2026	Short Term Effects of Semaglutide on Body Composition and Performance Morten Hostrup, PhD · Caloric Restriction, Body Composition	Not Yet Recruiting

Showing the 40 most recent of 802.

Semax: 0 registered trials

No registered trial names this peptide as an intervention (intervention search; a trial filed under another name or a combination product would not appear here).

sermorelin: 27 registered trials

Trial	Title	Status
NCT06554717 Phase 2 · n=100 · 2025	Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV Massachusetts General Hospital · HIV-1-infection, Frailty	Recruiting
NCT03375788 Phase 2 · n=51 · 2019 · results posted	Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk Massachusetts General Hospital · Non-Alcoholic Fatty Liver Disease, Obesity	Completed
NCT02553603 Phase 1 · n=22 · 2017	The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment The University of Texas Medical Branch, Galveston · Mild Cognitive Impairment	Completed
NCT03031535 Phase 1 · n=32 · 2017	Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers Dauntless Pharmaceuticals · Healthy Volunteer Study	Completed
NCT02736591 Phase 3 · n=210 · 2016	Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response Cairo University · Subfertility	Unknown
NCT02196831 n/a · n=61 · 2015 · results posted	Tesamorelin Effects on Liver Fat and Histology in HIV Massachusetts General Hospital · Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD)	Completed
NCT02271282 Phase 1 · n=40 · 2014	Estradiol-Receptor Blockade in Older Men and Women Mayo Clinic · Normal Healthy Volunteers	Completed
NCT02507245 n/a · n=48 · 2014	Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD) Stefania La Grutta, MD · Growth Hormone Deficiency	Completed
NCT01632592 n/a · 2014	Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue Massachusetts General Hospital · Abdominal Obesity	Withdrawn
NCT01410799 Phase 2 · n=13 · 2011 · results posted	Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly University of Pennsylvania · Hormone Deficiency, Aging	Terminated
NCT01359488 Phase 1 · n=50 · 2011	VRS-317 in Adult Subjects With Growth Hormone Deficiency Versartis Inc. · Growth Hormone Deficiency	Completed
NCT01263717 n/a · n=54 · 2010 · results posted	Effects of Growth Hormone Releasing Hormone in HIV Massachusetts General Hospital · HIV, HIV Lipodystrophy	Completed
NCT00850564 n/a · n=15 · 2009 · results posted	Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men Massachusetts General Hospital · Healthy Volunteers	Completed
NCT00795210 n/a · n=25 · 2009 · results posted	Effects of Short-term Growth Hormone in HIV-infected Patients Massachusetts General Hospital · HIV Lipodystrophy	Completed
NCT00675506 Phase 2 · n=60 · 2008 · results posted	Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Massachusetts General Hospital · Abdominal Obesity, Growth Hormone Deficiency	Completed
NCT02012556 Phase 1 · n=18 · 2008	Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients Theratechnologies · HIV	Completed
NCT00807365 Phase 2 · n=5 · 2007 · results posted	Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly Johns Hopkins University · Elderly	Terminated
NCT00608023 Phase 3 · n=263 · 2007 · results posted	TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy Theratechnologies · Lipodystrophy, HIV Infections	Completed
NCT00324064 n/a · n=90 · 2007	Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing Children's Mercy Hospital Kansas City · Growth Hormone Deficiency	Completed
NCT00720902 Phase 4 · n=7 · 2007 · results posted	Adult Growth Hormone Deficiency and Cardiovascular Risk Columbia University · Growth Hormone Deficiency	Terminated
NCT00257712 Phase 2 · n=151 · 2006	SMART: Somatotrophics, Memory, and Aging Research Trial University of Washington · Aging, Mild Cognitive Impairment	Completed
NCT00123253 Phase 3 · n=412 · 2005	TH9507 in Patients With HIV-Associated Lipodystrophy Theratechnologies · HIV Infections, Lipodystrophy	Completed
NCT00791843 Phase 2 · n=3 · 2004 · results posted	The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure University of Pennsylvania · Congestive Heart Failure	Completed
NCT01060488 Phase 3 · n=69 · 2004	Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency Merck KGaA, Darmstadt, Germany · Growth Hormone Deficiency	Completed
NCT03018886 n/a · n=160 · 2001	Diagnosing Adult Growth Hormone Deficiency Helsinki University Central Hospital · Growth Hormone Deficiency	Completed
NCT00000380 n/a · 1996	Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances University of Washington · Sleep Disorders	Completed
NCT00004332 n/a · n=148 · 1993	Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly National Center for Research Resources (NCRR) · Acromegaly	Completed

SLU-PP-332: 0 registered trials

No registered trial names this peptide as an intervention (intervention search; a trial filed under another name or a combination product would not appear here).

survodutide: 29 registered trials

Trial	Title	Status
NCT07855900 Phase 3 · n=350 · 2026	SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weig Boehringer Ingelheim · Obesity	Not Yet Recruiting
NCT07850063 Phase 3 · n=600 · 2026	ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Boehringer Ingelheim · Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease	Not Yet Recruiting
NCT07850050 Phase 3 · n=600 · 2026	SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have F Boehringer Ingelheim · Obesity	Not Yet Recruiting
NCT07768813 Phase 1 · n=44 · 2026	A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women Wit Boehringer Ingelheim · Healthy, Obesity	Active Not Recruiting
NCT07754461 Phase 3 · n=600 · 2026	A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar Boehringer Ingelheim · Type 2 Diabetes	Recruiting
NCT07407348 Phase 1 · n=80 · 2026	A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Boehringer Ingelheim · Healthy, Obesity	Active Not Recruiting
NCT07413913 Phase 1 · n=56 · 2026	A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Boehringer Ingelheim · Healthy, Obesity	Completed
NCT07206290 Phase 2 · n=120 · 2026	Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease University Medical Center Groningen · Chronic Kidney Disease	Not Yet Recruiting
NCT07221591 Phase 1 · n=100 · 2025	A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Boehringer Ingelheim · Healthy	Completed
NCT07071974 Phase 1 · n=16 · 2025	A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body Boehringer Ingelheim · Healthy	Completed
NCT06745284 Phase 1 · n=64 · 2025	A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity Boehringer Ingelheim · Obesity	Active Not Recruiting
NCT06772532 Phase 1 · n=30 · 2025	A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body Boehringer Ingelheim · Healthy	Completed
NCT06632457 Phase 3 · n=1590 · 2024	LIVERAGE™ – Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis Boehringer Ingelheim · Metabolic Dysfunction Associated Steatohepatitis	Recruiting
NCT05202353 Phase 1 · n=29 · 2024	A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver Boehringer Ingelheim · Obesity	Active Not Recruiting
NCT06632444 Phase 3 · n=1800 · 2024	LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibros Boehringer Ingelheim · Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis	Recruiting
NCT06564441 Phase 1 · n=34 · 2024	A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overw Boehringer Ingelheim · Overweight, Obesity	Completed
NCT06492135 Phase 1 · n=30 · 2024	A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body Boehringer Ingelheim · Overweight, Obesity	Completed
NCT06352411 Phase 1 · n=42 · 2024	A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems Boehringer Ingelheim · Healthy, Renal Impairment	Completed
NCT06309992 Phase 3 · n=218 · 2024	A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non Boehringer Ingelheim · Obesity, Non-Alcoholic SteatoHepatitis (NASH)	Completed
NCT06200467 Phase 1 · n=110 · 2024	A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity Boehringer Ingelheim · Overweight, Obesity	Completed
NCT06214741 Phase 3 · n=307 · 2024	A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight Boehringer Ingelheim · Obesity, Overweight	Completed
NCT06176365 Phase 3 · n=274 · 2024	A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease Boehringer Ingelheim · Obesity	Completed
NCT05896384 Phase 1 · n=32 · 2023	A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Bloo Boehringer Ingelheim · Healthy	Completed
NCT06066528 Phase 3 · n=755 · 2023	A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight Boehringer Ingelheim · Obesity, Diabetes Mellitus, Type 2	Completed
NCT06066515 Phase 3 · n=726 · 2023	A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Boehringer Ingelheim · Obesity	Completed
NCT06077864 Phase 3 · n=5530 · 2023	A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ – CVOT) Boehringer Ingelheim · Obesity	Completed
NCT05296733 Phase 1 · n=82 · 2022	A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People Wi Boehringer Ingelheim · Healthy, Liver Diseases	Completed
NCT04771273 Phase 2 · n=295 · 2021 · results posted	A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) Boehringer Ingelheim · Non-alcoholic Steatohepatitis (NASH)	Completed
NCT04667377 Phase 2 · n=387 · 2021 · results posted	A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight Boehringer Ingelheim · Obesity	Completed

TB-500: 17 registered trials

Trial	Title	Status
NCT07586865 Phase 2 · n=189 · 2026	Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction Beijing Northland Biotech. Co., Ltd. · Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall	Not Yet Recruiting
NCT05555589 Phase 3 · n=70 · 2023	Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 ReGenTree, LLC · Neurotrophic Keratopathy	Completed
NCT05984134 Phase 2 · n=90 · 2022	Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction Beijing Northland Biotech. Co., Ltd. · Acute Myocardial Infarction	Completed
NCT05485818 Phase 2 · n=62 · 2020	Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction Beijing Northland Biotech. Co., Ltd. · Acute Myocardial Infarction	Completed
NCT01311518 Phase 2 · 2019	A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction RegeneRx Biopharmaceuticals, Inc. · Acute Myocardial Infarction, ST Elevation Myocardial Infarction	Withdrawn
NCT03937882 Phase 3 · n=700 · 2019 · results posted	Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 ReGenTree, LLC · Dry Eye Syndromes, Dry Eye	Completed
NCT04555850 Phase 1 · n=30 · 2018	A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers Beijing Northland Biotech. Co., Ltd. · Healthy	Completed
NCT04555824 Phase 1 · n=54 · 2017	A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers Beijing Northland Biotech. Co., Ltd. · Healthy	Completed
NCT02974907 Phase 3 · n=601 · 2016 · results posted	Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 ReGenTree, LLC · Dry Eye Syndrome	Completed
NCT02597803 Phase 2/Phase 3 · n=317 · 2015	Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 ReGenTree, LLC · Dry Eye Syndrome	Completed
NCT01387347 Phase 2 · n=72 · 2011 · results posted	Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye ReGenTree, LLC · Dry Eye Syndrome, Dry Eye	Completed
NCT01393132 Phase 2 · n=9 · 2011 · results posted	Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye Michigan Cornea Consultants, PC · Dry Eye, Sjogren's Syndrome	Completed
NCT00743769 Phase 1 · 2008	A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers RegeneRx Biopharmaceuticals, Inc. · Myocardial Infarction, Myocardial Ischemia	Withdrawn
NCT00598871 Phase 2 · n=12 · 2007 · results posted	A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds ReGenTree, LLC · Diabetes	Terminated
NCT00832091 Phase 2 · n=72 · 2006 · results posted	Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers RegeneRx Biopharmaceuticals, Inc. · Venous Stasis Ulcers	Completed
NCT00382174 Phase 2 · n=72 · 2006 · results posted	Study of Thymosin Beta 4 in Patients With Pressure Ulcers RegeneRx Biopharmaceuticals, Inc. · Pressure Ulcers	Completed
NCT00311766 Phase 2 · n=30 · 2006 · results posted	A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa RegeneRx Biopharmaceuticals, Inc. · Epidermolysis Bullosa	Terminated

Teriparatide: 182 registered trials

Trial	Title	Status
NCT06303284 Phase 1/Phase 2 · n=54 · 2027	PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot) University of Calgary · Lower Extremity Fractures, Pelvis	Not Yet Recruiting
NCT07579936 Phase 2 · n=200 · 2026	A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis	Recruiting
NCT07497503 Phase 1 · n=48 · 2026	A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants Syneos Health · Healthy Volunteers	Recruiting
NCT07242612 n/a · n=40 · 2025	Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis Khyber Medical University Peshawar · Osteoporosis, Osteoporosis, Postmenopausal	Completed
NCT06898060 Phase 3 · n=282 · 2025	To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at H Qilu Pharmaceutical Co., Ltd. · Postmenopausal Women With Osteoporosis	Not Yet Recruiting
NCT06951776 n/a · n=28 · 2025	Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis Peking University Third Hospital · Circadian Rhythm Disorders, Osteoporosis	Not Yet Recruiting
NCT06558188 Phase 4 · n=50 · 2025	Combined Anabolic Therapy Massachusetts General Hospital · Osteoporosis, Postmenopausal, Osteoporosis	Recruiting
NCT06644040 Phase 1 · n=24 · 2024	A Study of TeriQ Patch in Healthy Adult Female Participants QuadMedicine · Osteoporosis	Completed
NCT06264609 Phase 4 · n=40 · 2024	Precision Medicine Approach for Osteoporosis – Follow Up Study Paul F Netzel · Osteoporosis	Enrolling By Invitation
NCT06164795 n/a · n=150 · 2023	Sequential Therapies After Osteoanabolic Treatment 424 General Military Hospital · Osteoporosis, Postmenopausal	Recruiting
NCT06061354 Phase 4 · n=42 · 2023	Teriparatide on Maxillary Sinus Floor Osseointegration Universidad de Valparaiso · Bone Regeneration	Unknown
NCT05866029 n/a · n=2478 · 2023	Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture Peking Union Medical College Hospital · Osteoporotic Fractures	Recruiting
NCT05965167 Phase 1 · n=45 · 2023	Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo Entera Bio Ltd. · Hypoparathyroidism, Osteoporosis	Completed
NCT06842758 n/a · n=40 · 2023	Relationship Between Thoracic Hyperkyphosis and Fall Risk in Women with Fragility Vertebral Fractures University of Palermo · Osteoporosis, Hyperkyphosis	Active Not Recruiting
NCT04589819 Phase 4 · n=183 · 2022	Fracture Recovery for Returning to Duty (Teriparatide STRONG) University of South Carolina · Stress Fracture of Tibia or Fibula	Enrolling By Invitation
NCT05151484 Phase 4 · n=60 · 2022	Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover Madhumathi Rao · Age-Related Osteoporosis	Active Not Recruiting
NCT05164614 Phase 1 · n=50 · 2022	Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule RANI Therapeutics · Healthy Volunteers	Completed
NCT04522622 Phase 4 · n=48 · 2021	Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease Ditte Hansen · Adynamic Bone Disease, Chronic Kidney Diseases	Recruiting
NCT07028320 Phase 3 · n=493 · 2021	To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis	Completed
NCT04974723 n/a · n=22054 · 2021 · results posted	Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women Radius Health, Inc. · Osteoporosis, Postmenopausal	Completed
NCT05369013 n/a · n=188 · 2021	Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or S STADA, Spain · Osteoporosis	Unknown
NCT04473989 Phase 2 · n=80 · 2021	Weekly Use of Teriparatide to Accelerate Healing of Distal Radius Fracture Peking University Third Hospital · Colles' Fracture	Unknown
NCT04921124 Phase 3 · n=30 · 2021	Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes Norfolk and Norwich University Hospitals NHS Foundation Trust · Stress Fracture	Completed
NCT04750460 Phase 3 · n=20 · 2021	Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Saint Petersburg State University, Russia · Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder	Completed
NCT04669782 n/a · n=99 · 2020	Effect of Vitamin K Supplementation on Circulating Levels of Osteocalcin on the Bone Metabolism and Aging University of Milano Bicocca · Bone Metabolism Disorder, Aging Disorder	Terminated
NCT05366621 n/a · n=216155 · 2020	Post-fracture Medication and Mortality National Cheng-Kung University Hospital · Osteoporosis, Osteoporosis Fracture	Completed
NCT04879420 n/a · n=12757 · 2020	Replication of the VERO Osteoporosis Trial in Healthcare Claims Data Brigham and Women's Hospital · Osteoporosis	Completed
NCT05018637 Phase 2 · n=30 · 2020	Efficacy of WJ-derived Mesenchymal Stem Cells in Combination With Parathyroid Hormone for Vertebral Compression Fracture Inbo Han · Vertebral Compression Fracture, Osteoporotic Fractures	Unknown
NCT04747392 Phase 1 · n=64 · 2020	Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Osteoporosis	Completed
NCT03217513 n/a · 2020	Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis Edward Fox · Osteoporosis, Knee Osteoarthritis	Withdrawn
NCT04196855 Phase 3 · n=136 · 2019	Study of Teriparatide in Stress Fracture Healing University of East Anglia · Stress Fracture, Parathyroid Hormone	Unknown
NCT04026256 Phase 4 · n=37 · 2019 · results posted	Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration Massachusetts General Hospital · Postmenopausal Osteoporosis	Completed
NCT03994172 Phase 4 · n=40 · 2019 · results posted	Novel Combination Therapy for Osteoporosis in Men VA Office of Research and Development · Male Osteoporosis	Completed
NCT04003467 Phase 2 · n=161 · 2019	A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass Entera Bio Ltd. · Osteoporosis	Completed
NCT04206618 n/a · n=220 · 2019	Circulating Myokine Levels and Bone Metabolism 424 General Military Hospital · Osteoporosis, Postmenopausal	Completed
NCT04126941 n/a · n=9 · 2019	Monocentric Study on the Use of Teriparatide in Children With hypoparathyroïdism Hospices Civils de Lyon · Hypoparathyroidism	Unknown
NCT03770338 n/a · n=192 · 2019	Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery The University of Hong Kong · Osteoporosis, Fusion of Spine, Lumbar Region	Active Not Recruiting
NCT03702140 Phase 2 · n=90 · 2018	Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy Shinshu University · Osteoporosis	Unknown
NCT03720886 Phase 1/Phase 2 · n=148 · 2018	G56W1 in Women With Postmenopausal Osteoporosis Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Osteoporosis	Unknown
NCT02932501 n/a · n=518 · 2017	Medication-related Osteonecrosis of the Jaw (MRONJ) Registry AO Clinical Investigation and Publishing Documentation · Medication-related Osteonecrosis of the Jaw, Bisphosphonate-Associated Osteonecrosis of the Jaw	Unknown

Showing the 40 most recent of 182.

tesamorelin: 23 registered trials

Trial	Title	Status
NCT06554717 Phase 2 · n=100 · 2025	Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV Massachusetts General Hospital · HIV-1-infection, Frailty	Recruiting
NCT03826160 n/a · n=23 · 2019	Growth Hormone Dynamics and Cardiac Steatosis in HIV Massachusetts General Hospital · Human Immunodeficiency Virus, Lipodystrophy	Completed
NCT03375788 Phase 2 · n=51 · 2019 · results posted	Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk Massachusetts General Hospital · Non-Alcoholic Fatty Liver Disease, Obesity	Completed
NCT03150511 Phase 2 · n=36 · 2018	Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury Johns Hopkins University · Peripheral Nerve Injuries	Recruiting
NCT03226821 Phase 4 · n=6 · 2018 · results posted	Body Composition and Adipose Tissue in HIV Columbia University · HIV Lipodystrophy Syndrome, Growth Hormone Deficiency	Terminated
NCT02553603 Phase 1 · n=22 · 2017	The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment The University of Texas Medical Branch, Galveston · Mild Cognitive Impairment	Completed
NCT02572323 Phase 2 · n=73 · 2017 · results posted	Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons University of California, San Diego · Mild Cognitive Impairment	Completed
NCT02931474 Phase 2 · 2016	Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomn National Institute of Nursing Research (NINR) · Sleep Disorder, Traumatic Brain Injury	Withdrawn
NCT02196831 n/a · n=61 · 2015 · results posted	Tesamorelin Effects on Liver Fat and Histology in HIV Massachusetts General Hospital · Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD)	Completed
NCT01632592 n/a · 2014	Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue Massachusetts General Hospital · Abdominal Obesity	Withdrawn
NCT01579695 n/a · n=391 · 2013	Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Theratechnologies · HIV	Terminated
NCT01591902 Phase 4 · n=129 · 2012	Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® Theratechnologies · Diabetic Retinopathy, HIV	Terminated
NCT01788462 n/a · 2012	Egrifta Replacement and Sleep Disordered Breathing Johns Hopkins University · Lipodystrophy	Withdrawn
NCT01388920 Phase 2 · n=3 · 2011 · results posted	Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting Theratechnologies · Chronic Obstructive Pulmonary Disease (COPD)	Terminated
NCT01263717 n/a · n=54 · 2010 · results posted	Effects of Growth Hormone Releasing Hormone in HIV Massachusetts General Hospital · HIV, HIV Lipodystrophy	Completed
NCT00850564 n/a · n=15 · 2009 · results posted	Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men Massachusetts General Hospital · Healthy Volunteers	Completed
NCT00795210 n/a · n=25 · 2009 · results posted	Effects of Short-term Growth Hormone in HIV-infected Patients Massachusetts General Hospital · HIV Lipodystrophy	Completed
NCT00675506 Phase 2 · n=60 · 2008 · results posted	Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Massachusetts General Hospital · Abdominal Obesity, Growth Hormone Deficiency	Completed
NCT02012556 Phase 1 · n=18 · 2008	Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients Theratechnologies · HIV	Completed
NCT00608023 Phase 3 · n=263 · 2007 · results posted	TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy Theratechnologies · Lipodystrophy, HIV Infections	Completed
NCT00257712 Phase 2 · n=151 · 2006	SMART: Somatotrophics, Memory, and Aging Research Trial University of Washington · Aging, Mild Cognitive Impairment	Completed
NCT00123253 Phase 3 · n=412 · 2005	TH9507 in Patients With HIV-Associated Lipodystrophy Theratechnologies · HIV Infections, Lipodystrophy	Completed
NCT01264497 Phase 2 · n=55 · 2002	Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes Theratechnologies · Type 2 Diabetes	Completed

thymosin alpha-1: 67 registered trials

Trial	Title	Status
NCT07382375 n/a · n=300 · 2027	AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection Nanjing Medical University · Aortic Aneurysm and Dissection	Not Yet Recruiting
NCT07884201 Phase 2 · n=572 · 2026	Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment Fudan University · Breast Cancer, TNBC – Triple-Negative Breast Cancer	Not Yet Recruiting
NCT07866118 n/a · n=60 · 2026	Thymalfasin for Immune Recovery in Adults With Sepsis Shanghai Zhongshan Hospital · Sepsis, Immunosuppression	Recruiting
NCT07780721 Phase 2 · n=31 · 2026	Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer The Affiliated Hospital of Putian University · Esophageal Cancer	Not Yet Recruiting
NCT07922954 Phase 4 · n=36 · 2026	Thymosin Alpha 1 and IgM Levels in Sepsis Southeast University, China · Sepsis, Septic Shock	Active Not Recruiting
NCT07675980 Phase 2/Phase 3 · n=136 · 2026	Thymosin-α1 for Recurrent Implantation Failure Fakih IVF Fertility Center · Recurrent Implantation Faliure	Recruiting
NCT07103395 Phase 2 · n=56 · 2026	A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Loc Sun Yat-sen University · Lung Cancer (NSCLC)	Recruiting
NCT07277439 Phase 2 · n=48 · 2025	Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma The First Affiliated Hospital with Nanjing Medical University · Gastric Cancer	Recruiting
NCT07103408 Phase 2 · n=56 · 2025	A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer Sun Yat-sen University · Small-Cell Lung Cancer (SCLC)	Not Yet Recruiting
NCT06966687 n/a · n=200 · 2025	Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection S Nanjing Medical University · Aortic Dissection, Aortic Dissection Aneurysm	Enrolling By Invitation
NCT06829355 Phase 2 · n=52 · 2025	"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" Beijing Friendship Hospital · MCRC	Recruiting
NCT06821100 Phase 1 · n=75 · 2024	Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine The Methodist Hospital Research Institute · Vaccine Response, COVID-19 Vaccine	Recruiting
NCT06607926 n/a · n=40 · 2024	Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC Xuanwu Hospital, Beijing · Resectable Non-Small-Cell Lung Cancer	Unknown
NCT06584006 Phase 2 · n=50 · 2024	Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors The First Affiliated Hospital of Xiamen University · Hematological Malignancy, Lymphocytopenia	Recruiting
NCT06573398 Phase 2 · n=20 · 2024	Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC Ruijin Hospital · Carcinoma, Pancreatic Ductal	Not Yet Recruiting
NCT06598839 n/a · n=40 · 2024	Immuno-effect of Tα1 for Stage I NSCLC Yousheng Mao · Non Small Cell Lung Cancer	Unknown
NCT06461910 Phase 2 · n=30 · 2024	Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcino Zekuan Xu · Gastric Cancer, Esophagogastric Junction Adenocarcinoma	Recruiting
NCT06552598 Phase 1 · n=97 · 2024	The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies Tongji Hospital · Cervical Cancer, Gynecologic Malignancies	Recruiting
NCT06056804 Phase 2 · n=20 · 2024	Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer Beijing Friendship Hospital · Locally Advanced Rectal Cancer	Active Not Recruiting
NCT06401447 n/a · n=50 · 2023	TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma Fudan University · Esophageal Squamous Cell Carcinoma	Active Not Recruiting
NCT06024356 n/a · n=47 · 2023	Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer Beijing Friendship Hospital · Colorectal Neoplasms	Completed
NCT06178146 Phase 4 · n=40 · 2023	Thymosin Alpha-1 for irAE Secondary to ICIs Jun Wang · IrAE	Unknown
NCT06139419 Phase 2 · n=114 · 2023	The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCL Sun Yat-sen University · Non-small Cell Lung Cancer	Completed
NCT07644897 Phase 2 · n=55 · 2023	Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma Sun Yat-sen University · Melanoma, Immune-related Adverse Event	Recruiting
NCT05790447 Phase 2 · n=60 · 2023	Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors Second Affiliated Hospital of Soochow University · Advanced Solid Tumor, Refractory Tumor	Unknown
NCT05658692 Phase 4 · n=1000 · 2022	Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome Second Affiliated Hospital, Zhejiang University, School of Medicine · Acute Respiratory Distress Syndrome	Unknown
NCT05487469 n/a · n=200 · 2022	Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass Nanjing Medical University · Rheumatic Heart Disease, Cardiopulmonary Bypass	Unknown
NCT05339529 n/a · n=600 · 2022	Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II Nanjing Medical University · Acute Aortic Syndrome, Aortic Dissection Type A	Completed
NCT04963712 Early Phase 1 · n=20 · 2021	Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder Shanghai Public Health Clinical Center · HIV-1-infection	Completed
NCT04901104 n/a · n=900 · 2021	Long-term Prognosis of Patients With Sepsis After Immunotherapy Sun Yat-sen University · Long-term Effects of Thymosin Alpha 1 Treatment	Not Yet Recruiting
NCT05086614 Phase 3 · n=2500 · 2021	Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer Fudan University · Stage II Colorectal Cancer, Stage III Colorectal Cancer	Recruiting
NCT04428008 Phase 2 · n=189 · 2021 · results posted	Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients William B. Ershler, MD · COVID-19	Completed
NCT04524169 Phase 4 · n=100 · 2020	Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain RenJi Hospital · Osteoporotic Pain	Unknown
NCT04487444 Phase 2 · n=56 · 2020	Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection Rhode Island Hospital · Covid19	Terminated
NCT04320238 Phase 3 · n=2944 · 2020	Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff Shanghai Jiao Tong University School of Medicine · 2019 Novel Coronavirus Infection	Unknown
NCT03659578 Phase 2 · n=69 · 2018	Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer Sun Yat-sen University · Non-small Cell Lung Cancer	Completed
NCT02473406 Phase 4 · n=508 · 2018	Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis Weiqin Li · Pancreatitis, Acute Necrotizing	Completed
NCT03448744 Phase 4 · n=240 · 2017	Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients Wen-hong Zhang · Chronic Hepatitis b	Unknown
NCT03082885 n/a · n=120 · 2017	The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF Sun Yat-sen University · Liver Failure	Completed
NCT02976740 Phase 2 · n=48 · 2016	SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy The First Affiliated Hospital of Xiamen University · Lung Cancer Metastatic	Unknown

Showing the 40 most recent of 67.

tirzepatide: 313 registered trials

Trial	Title	Status
NCT07728318 n/a · n=52 · 2027	Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients Akhtar Saeed Medical and Dental College · Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight	Not Yet Recruiting
NCT07265752 Phase 2 · n=6 · 2027	Tirzepatide for the Treatment of Cannabis Use Disorder Brigham and Women's Hospital · Cannabis Use Disorder	Not Yet Recruiting
NCT07926152 n/a · n=94 · 2027	Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes German Diabetes Center · Type 2 Diabetes (T2DM), Obesity & Overweight	Not Yet Recruiting
NCT07847515 n/a · n=80 · 2027	Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients Nanjing First Hospital, Nanjing Medical University · Obesity / Overweight	Not Yet Recruiting
NCT07787936 n/a · n=150 · 2027	GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry Miedziowe Centrum Zdrowia SA · Heart Failure With Preserved Ejection Fraction, Obesity	Not Yet Recruiting
NCT07622992 n/a · n=96 · 2027	Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery Mario Musella MD · Obesity (BMI > 35) and Diabetes Mellitus, Obesity (BMI > 35) and Dyslipemia	Not Yet Recruiting
NCT07929233 n/a · n=250 · 2027	24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor Portuguese Oncology Institute, Coimbra · Retained Gastric Content, Delayed Gastric Emptying	Not Yet Recruiting
NCT07829198 Phase 3 · n=70 · 2027	Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, P Universidade do Porto · Obesity	Not Yet Recruiting
NCT07078838 Phase 2 · n=40 · 2027	Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer UNC Lineberger Comprehensive Cancer Center · Endometrial Cancer, Endometrial Intraepithelial Neoplasia	Not Yet Recruiting
NCT07889648 Phase 3 · n=948 · 2026	A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar C Hoffmann-La Roche · Type 2 Diabetes Mellitus	Not Yet Recruiting
NCT07881432 Phase 3 · n=2115 · 2026	A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes Eli Lilly and Company · Obesity	Not Yet Recruiting
NCT07832084 Phase 4 · n=60 · 2026	Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s Jing Luo · Obesity & Overweight, Cardiometabolic Health Indicators	Not Yet Recruiting
NCT06180616 Phase 2 · n=40 · 2026	Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity Royal North Shore Hospital · Type 1 Diabetes Mellitus, Overweight and Obesity	Not Yet Recruiting
NCT07468552 Phase 2 · n=100 · 2026	Trial of Tirzepatide for the Treatment of Cannabis Use Disorder National Institute on Drug Abuse (NIDA) · Cannabis Use Disorder	Not Yet Recruiting
NCT07855900 Phase 3 · n=350 · 2026	SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weig Boehringer Ingelheim · Obesity	Not Yet Recruiting
NCT07796477 Phase 2 · n=240 · 2026	A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin CSPC Ouyi Pharmaceutical Co., Ltd. · T2DM (Type 2 Diabetes Mellitus)	Not Yet Recruiting
NCT07878494 n/a · n=30 · 2026	Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia Stanford University · Post-Bariatric Hypoglycemia	Not Yet Recruiting
NCT07812636 Early Phase 1 · n=15 · 2026	Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer Milton S. Hershey Medical Center · Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia	Not Yet Recruiting
NCT07609160 n/a · n=108 · 2026	Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Functi Acibadem University · Obesity, Sarcopenia	Not Yet Recruiting
NCT07349641 Phase 2 · n=55 · 2026	A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometr National Cancer Institute (NCI) · Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	Not Yet Recruiting
NCT07027969 Phase 4 · n=100 · 2026	Metabolic Surgery for Atrial Fibrillation Elimination Ali Aminian · Atrial Fibrillation, Obesity and Obesity-related Medical Conditions	Not Yet Recruiting
NCT07758231 Phase 1 · n=5 · 2026	Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics University of Wisconsin, Madison · GLP-1, Alcohol	Not Yet Recruiting
NCT07099742 n/a · n=364 · 2026	Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) Dr. Md. Alimur Reza · Obesity	Not Yet Recruiting
NCT07900074 Phase 4 · n=80 · 2026	Mechanisms of Weight Loss: Tirzepatide vs Semaglutide McMaster University · Obesity (Disorder)	Recruiting
NCT07881783 n/a · n=3718 · 2026	A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Novartis Pharmaceuticals · Plaque Psoriasis	Not Yet Recruiting
NCT07893457 Phase 4 · n=30 · 2026	Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity Mayo Clinic · Obese Adults	Not Yet Recruiting
NCT07825857 Phase 2 · n=228 · 2026	Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder University of Texas Southwestern Medical Center · Methamphetamine Use Disorder	Recruiting
NCT07929571 n/a · n=150 · 2026	Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight Loss Technical University of Munich · Obesity (Disorder)	Not Yet Recruiting
NCT07782359 Phase 1 · n=30 · 2026	Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib University of Chicago · Lung Cancer	Recruiting
NCT07881458 Phase 3 · n=1000 · 2026	A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes Eli Lilly and Company · Obesity, Overweight	Recruiting
NCT07889453 n/a · n=650 · 2026	Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide LMC Diabetes & Endocrinology Ltd. · Obesity, Type 2 Diabetes (T2D)	Active Not Recruiting
NCT07874828 Phase 2 · n=30 · 2026	PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors – A Phas M.D. Anderson Cancer Center · Sarcoma,Soft Tissue	Recruiting
NCT07868354 Phase 1 · n=60 · 2026	A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment Novo Nordisk A/S · Overweight, Obesity	Recruiting
NCT07777575 Phase 4 · n=150 · 2026	Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide Technical University of Munich · Obesity (BMI>30)	Recruiting
NCT07846865 Phase 2/Phase 3 · n=256 · 2026	Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea Woolcock Institute of Medical Research · Sleep Apnoea, Obesity & Overweight	Not Yet Recruiting
NCT07809568 n/a · n=330 · 2026	Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes Universiti Sains Malaysia · Prediabetes or Overweight, Obesity Type 2 Diabetes Mellitus	Not Yet Recruiting
NCT07906041 Phase 2 · n=22 · 2026	Tirzepatide and Organ-specific Biological Aging Atria Research and Global Health Institute (ARGHI) · Longevity, Preventive Medicine	Enrolling By Invitation
NCT07387796 n/a · n=40 · 2026	Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation The University of Texas at Dallas · Drug Discontinuation, Substance Use Disorders	Recruiting
NCT07845500 Phase 3 · n=660 · 2026	A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overwe Pfizer · Obesity, Overweight and/or Obesity	Recruiting
NCT07817875 Phase 3 · n=150 · 2026	Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Yea Eli Lilly and Company · Obesity	Recruiting

Showing the 40 most recent of 313.

Change log

2026-11-11: 3 new trial(s) registered (NCT07927972, NCT07929233, NCT07929571); 4 status change(s); refreshed from ClinicalTrials.gov (3303 records).

2026-11-10: 3 new trial(s) registered (NCT07924553, NCT07924618, NCT07926152); 3 status change(s); refreshed from ClinicalTrials.gov (3298 records).

2026-11-07: 5 new trial(s) registered (NCT07921485, NCT07922083, NCT07922954, NCT07923357, NCT07923630); 3 status change(s); refreshed from ClinicalTrials.gov (3293 records).

2026-11-06: 1 new trial(s) registered (NCT07919405); 3 status change(s); refreshed from ClinicalTrials.gov (3288 records).

2026-11-05: 4 status change(s); refreshed from ClinicalTrials.gov (3285 records).

2026-11-04: 1 new trial(s) registered (NCT07913685); refreshed from ClinicalTrials.gov (3285 records).

2026-11-03: 3 new trial(s) registered (NCT07908940, NCT07909889, NCT07911046); 6 status change(s); refreshed from ClinicalTrials.gov (3284 records).

2026-10-31: 2 new trial(s) registered (NCT07906041, NCT07907965); 1 status change(s); refreshed from ClinicalTrials.gov (3279 records).

2026-10-30: 1 new trial(s) registered (NCT07902752); 3 status change(s); refreshed from ClinicalTrials.gov (3277 records).

2026-10-29: 4 new trial(s) registered (NCT04466566, NCT07900074, NCT07900438, NCT07901777); 2 status change(s); refreshed from ClinicalTrials.gov (3276 records).